



Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing *Plasmodium falciparum* chloroquine resistance transporter (PfCRT) inhibitory activity



Nicola Relitti ^{a, b}, Stefano Federico ^{a, b}, Luca Pozzetti ^{a, b}, Stefania Butini ^{a, b}, Stefania Lamponi ^{a, b}, Donatella Taramelli ^{c, b}, Sarah D'Alessandro ^{d, b}, Rowena E. Martin ^e, Sarah H. Shafik ^e, Robert L. Summers ^e, Simone K. Babij ^e, Annette Habluetzel ^{f, b}, Sofia Tapanelli ^{f, b}, Reto Caldelari ^g, Sandra Gemma ^{a, b, *}, Giuseppe Campiani ^{a, b}

^a Department of Biotechnology, Chemistry and Pharmacy (DoE 2018-2022), University of Siena, Via Aldo Moro 2, 53100 Siena, Italy

^b Centro Interuniversitario di Ricerche Sulla Malaria (CIRM), University of Milan, Milano, Italy

^c Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Pascal 36, 20133, Milan, Italy

^d Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133, Milan, Italy

^e Research School of Biology, Australian National University, Canberra, ACT, 2600, Australia

^f School of Pharmacy, University of Camerino, Piazza Cavour 19F, 62032, Camerino, Italy

^g Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012, Bern, Switzerland

ARTICLE INFO

Article history:

Received 16 December 2020

Received in revised form

21 January 2021

Accepted 21 January 2021

Available online 6 February 2021

Keywords:

Malaria

Plasmodium falciparum

Chloroquine resistance

PfCRT

Chemosensitization

Liver-stage antimalarial

Xenopus oocytes

ABSTRACT

Due to the surge in resistance to common therapies, malaria remains a significant concern to human health worldwide. In chloroquine (CQ)-resistant (CQ-R) strains of *Plasmodium falciparum*, CQ and related drugs are effluxed from the parasite's digestive vacuole (DV). This process is mediated by mutant isoforms of a protein called CQ resistance transporter (PfCRT). CQ-R strains can be partially re-sensitized to CQ by verapamil (VP), primaquine (PQ) and other compounds, and this has been shown to be due to the ability of these molecules to inhibit drug transport via PfCRT. We have previously developed a series of clotrimazole (CLT)-based antimalarial agents that possess inhibitory activity against PfCRT (**4a,b**). In our endeavor to develop novel PfCRT inhibitors, and to perform a structure-activity relationship analysis, we synthesized a new library of analogues. When the benzhydryl system was linked to a 4-aminoquinoline group (**5a-f**) the resulting compounds exhibited good cytotoxicity against both CQ-R and CQ-S strains of *P. falciparum*. The most potent inhibitory activity against the PfCRT-mediated transport of CQ was obtained with compound **5k**. When compared to the reference compound, benzhydryl analogues of PQ (**5i,j**) showed a similar activity against blood-stage parasites, and a stronger *in vitro* potency against liver-stage parasites. Unfortunately, in the *in vivo* transmission blocking assays, **5i,j** were inactive against gametocytes.

© 2021 Elsevier Masson SAS. All rights reserved.

1. Introduction

Despite recent progress in the fight against malaria, it remains a serious problem worldwide with more than 405,000 deaths in 2018 [1]. The current first-line treatments for malaria are the artemisinin-based combination therapies (ACTs), which are characterized by high

efficacy together with a fast action and thus reduced potential for the development of resistant parasite strains. However, in recent years some regions of Asia (the Greater Mekong Subregion) have reported a lower vulnerability of the malaria parasite to ACTs [2]. Given the importance of the ACTs for the treatment of drug-resistant malaria, it is necessary to search for new and affordable antiplasmodial drugs that are active against multiple stages of the *Plasmodium* life cycle and/or that are able to rescue older antimalarial drugs. Chloroquine (CQ, **1**, Fig. 1) was one of the first safe and effective antimalarials to be widely employed. It is characterized by potent and selective cytotoxic action against *Plasmodium falciparum*, together with a good

* Corresponding author. Department of Biotechnology, Chemistry and Pharmacy (DoE 2018-2022), University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.
E-mail address: gemma@unisi.it (S. Gemma).

Abbreviations

| | |
|------|---|
| ACTs | artemisinin-based combination therapies |
| CP | chlorpheniramine |
| CQ | chloroquine |
| CQ-R | CQ-resistant |
| CQ-S | chloroquine-sensitive |
| VP | verapamil |
| DCE | dichloroethane |
| DCM | dichloromethane |
| DFA | direct feeding assay |
| DMF | dimethylformamide |
| DMSO | dimethyl sulfoxide |
| DV | digestive vacuole |
| GFP | green fluorescent protein |

| | |
|---------|---|
| hpi | hours post infection |
| i.p | intraperitoneal |
| i.v | intravenous |
| MW | microwaves |
| PetEt | petroleum ether |
| PfCRT | <i>P. falciparum</i> chloroquine-resistance transporter |
| PQ | primaquine |
| CLT | clotrimazole |
| TBAF | tetrabutylammonium fluoride |
| TBDPSCI | <i>tert</i> -butyldiphenylchlorosilane |
| TEA | triethylamine |
| TFA | trifluoroacetic acid |
| THF | tetrahydrofuran |
| TZP | triazolopyrimidine |
| SAR | structure-activity relationship |




Fig. 1. Structure of chloroquine (1), verapamil (2), primaquine (3) and 4a,b.

safety profile and low-cost of the treatment regimen. However, after decades of use, a dramatic spread of CQ-resistant (CQ-R) strains of malaria parasites occurred [3]. The resistance of *P. falciparum* to CQ is related to an increased capacity of the parasite to expel the drug from the digestive vacuole (DV), which is its site of action. CQ-R parasites accumulate much less CQ in their DV than CQ-sensitive (CQ-S) parasites do [4,5], and the presence of a resistance-reverser (e.g., the calcium channel blocker verapamil, VP, **1**, Fig. 1) increases the accumulation of CQ in CQ-R parasites. The mechanism behind the CQ-efflux from the DV of *P. falciparum* has been established [6]. CQ is transported out of the DV by a mutant isoform of the *P. falciparum* chloroquine-resistance transporter (PfCRT) [7–10], a protein that localizes to the membrane of this organelle [11,12].

A cryo-electron microscopy structure of PfCRT (49 kDa) complexed with a recombinant PfCRT-specific antigen-binding fragment (50 kDa) has recently been published [7]. PfCRT consists of 424 amino acids, with ten transmembrane domains that cross the DV membrane. Expression of PfCRT at the surface of *Xenopus* oocytes has revealed that the isoforms of the protein associated with CQ resistance, such as the 'Dd2' variant (PfCRT^{Dd2}), mediate CQ transport [7,8]. By contrast, wild-type PfCRT (PfCRT^{3D7}) lacks significant CQ transport activity. From *in vitro* assays, it has been observed that the sensitivity of CQ-R *P. falciparum* strains to CQ can be partially restored by VP (**2**, Fig. 1) as well as by various other compounds, such as the liver-stage antimalarial primaquine (PQ, **3** Fig. 1) [5,13,14]. These CQ resistance-reversers do not usually affect the accumulation of CQ in the DV of CQ-S strains, and exert little or


no intrinsic antiparasmodial activity against the intraerythrocytic stage of *Plasmodium* [15]. Their mode of action arises from the inhibition of CQ transport via the mutant isoforms of PfCRT [14,16–18], thus reinstating the ability of CQ to accumulate inside the DV by a weak-base trapping mechanism [19]. Aside from its roles in the phenomenon of multidrug resistance [6], PfCRT is essential for the survival of the parasite [20]. Its natural function was recently revealed to be the efflux of large host-derived peptides (4–11 residues in length) from the DV, with PfCRT^{3D7} translocating a broader range of peptides and peptide mimics, and at a higher capacity, than almost all of the mutant isoforms (including PfCRT^{Dd2}) [21].

We have been pursuing the design and development of new antiparasmodial drugs endowed with various modes of actions [22,23]. These included clotrimazole (CLT)-based antiparasmodial agents as a novel scaffold able to interfere with heme metabolism inside the DV, as well as a new class of CQ-CLT-hybrid compounds [24–26]. Benzhydryl-derivatives belonging to the latter class, typified by compounds **4a,b** (Fig. 1), showed an excellent antiparasmodial activity profile against both CQ-S and CQ-R strains of *P. falciparum* *in vitro* and *in vivo*. These molecules share all or most of the following features: a weak basic heme-complexing group, a quinoline moiety (to provide the antiparasmodial effect), and a benzhydryl system presenting a basic group (to enable accumulation of the compound inside the DV via weak-base trapping). Most of these molecules showed good antiparasmodial potency against the CQ-R strains, which led us to explore the mechanisms involved in their activity. It was observed that both **4a** and **4b** were able to inhibit CQ transport via PfCRT^{Dd2} in the *Xenopus* oocyte expression system [24]. Encouraged by this discovery and the growing interest in PfCRT as a promising drug target [21,27–29], we investigated a series of new analogues of **4** in order to improve their activity against PfCRT^{Dd2} and to explore the structural features required for the inhibition of PfCRT^{Dd2}-mediated CQ transport, whilst maintaining the intrinsic antiparasmodial properties. Here, we designed and tested analogues **5a-k**, and **6c,h,i** (Table 1) to evaluate the effect of substitutions at (1) the benzhydryl moiety and (2) the quinoline ring on activity against PfCRT^{Dd2}-mediated CQ transport as well as on antiparasmodial activity. In addition, compounds **5l,m** were evaluated in an attempt to improve the inhibitory activity against PfCRT^{Dd2}.

2. Chemistry

Compounds **5a-k**, **5m** were synthesized as described in Schemes 1–4, while the synthesis of **5l** and **6a-i** is reported in the


Table 1
Antiplasmodial activity of compounds **5a-l**, **6c,h,i** and of reference compounds CQ (**1**), PQ (**3**) and **4a,b**.




| Compound | R ¹ | R ² | R ³ | X | IC ₅₀ (μM) D10 | IC ₅₀ (μM) W2 |
|---------------|----------------|----------------|----------------|----|---------------------------|--------------------------|
| 1 (CQ) | - | - | - | - | 0.022 | 0.280 |
| 3 (PQ) | - | - | - | - | 5.7 | 4.4 |
| 4a[24] | <i>m</i> -Cl | | | H | 0.025 | 0.033 |
| 4b[24] | <i>p</i> -Cl | | | H | 0.062 | 0.058 |
| 5a | <i>p</i> -Cl | | | H | 0.065 | 0.069 |
| 5b | <i>m</i> -Cl | | | H | 0.084 | 0.088 |
| 5c | <i>p</i> -Cl | | | H | 0.019 | 0.027 |
| 5d | <i>m</i> -Cl | | | H | 0.023 | 0.022 |
| 5e | <i>m</i> -OMe | | | H | 0.040 | 0.075 |
| 5f | <i>m</i> -OH | | | H | 0.179 | 0.475 |
| 5g | <i>p</i> -Cl | | | H | 3.70 | 2.70 |
| 5h | <i>p</i> -Cl | | | OH | 2.00 | 2.00 |
| 5i | <i>m</i> -Cl | | | H | 2.80 | 2.30 |
| 5j | <i>m</i> -Cl | | | H | 4.50 | 3.70 |
| 5k | <i>m</i> -Cl | | | H | 3.70 | 0.92 |
| 5l | - | - | - | - | 0.595 | 0.460 |
| 6c | <i>p</i> -Cl | | -OH | H | >15 | >15 |
| 6h | <i>p</i> -Cl | | =O | - | >15 | 8.6 |
| 6i | <i>p</i> -Cl | | -OH | H | >15 | 11 |

Supporting Information file (Schemes S1-5). For the synthesis of compounds **5a-f** and **5i,j** an approach that parallels our previously described synthetic pathway was followed (Scheme 1). Starting from the appropriate benzhydrols **6a-d**, the corresponding benzhydryl chlorides were obtained by treatment with SOCl_2 in dry DCM. These chlorides were used for the alkylation of the 7-chloro-4-aminoquinoline obtaining compounds **5a-d**. For the synthesis of compounds **5e,f**, benzhydrols intermediates **11** and **12** were prepared starting from aldehydes **8** and **9**. For the synthesis of intermediate **10**, the free OH group of **8** was protected to the corresponding silyl-derivative. Aldehydes **9** and **10** were then subjected to a lithium halogen exchange reaction to afford compounds **11** and **12**, respectively. Deprotection of the cyclic ketal of both compounds released the free aldehyde that was then submitted to a reductive amination protocol to afford the tertiary amines **13** and **14**. Starting from these latter compounds, the subsequent steps, namely chlorination to **15**, **16**, and reaction with 7-chloro-4-aminoquinolines, afforded protected derivatives **17** and **18**. Their deprotection afforded the final compounds **5e,f**. Following a similar reaction pathway, alkylation of 8-amino-6-methoxyquinoline with benzhydryl chlorides **19** and **20** (synthesized as reported [25,30]) afforded **21** and **5j**, respectively. Starting from **21**, final compound **5h** was obtained by acid-promoted *N*-Boc deprotection.

In Scheme 2 the synthesis of the final compounds **5g,h** is reported. 4,7-Dichloroquinoline (**22**) was converted to 7-chloro-4-methylquinoline by treatment with methylmagnesium bromide, in the presence of [1,2-bis(diphenylphosphino)ethane]dichloronickel (II) as catalyst [31]. The methyl group was oxidized to the corresponding aldehyde through a reaction carried out in the presence of *tert*-butyl iodide, DMSO, AcOH and FeCl_2 obtaining compound **23** [32]. This intermediate was used in the next Grignard




Scheme 1. Reagents and Conditions: a) SOCl_2 , DCM, 50 °C, 2 h; b) 4-amino-7-chloroquinoline CH_3CN , TEA, 80 °C, 12 h; c) TBDPSCI, imidazole, THF, 0–25 °C, 12 h; d) 2-(4-bromophenyl)-1,3-dioxolane, *n*-BuLi, THF, –70 °C, 2 h; e) HCl, 1 N, THF, 4 h, 25 °C; f) 1-Boc-piperazine, NaBH_3CN , 1% AcOH in EtOH, 12 h, 25 °C; g) 1 N HCl in MeOH, 40 °C, 30 min; h) TBAF, THF, 0–25 °C, 12 h; i) 8-amino-6-methoxy quinoline, CH_3CN , TEA, 80 °C, 12 h.



Scheme 2. Reagents and Conditions: a) Methylmagnesium bromide, [1,2-bis(diphenylphosphino)ethane]dichloronickel (II), Et_2O , 0–25 °C, 12 h; b) *tert*-butyl iodide, I_2 , FeCl_2 , TFA, DMSO, 80 °C, 6 h; c) 4-bromophenylmagnesium bromide, THF, 0–25 °C, 6 h; d) MnO_2 , CHCl_3 , 25 °C, 3 h; e) 2-(4-bromophenyl)-1,3-dioxolane, *n*-BuLi, THF, –70 °C, 2 h; f) acetone, H_2O , 140 W, 100 °C, 30 min; g) 1-Boc-piperazine, NaBH_3CN , EtOH, AcOH, 25 °C, 12 h; h) TFA, DCM, 25 °C, 1.5 h; i) H_3PO_2 , I_2 , AcOH, H_2O , 60 °C, 12 h.

reaction with 4-chlorophenylmagnesium bromide obtaining an alcohol intermediate that was oxidized to the ketone **24** with MnO_2 . This latter compound was submitted to a reaction with *n*-BuLi and 2-(4-bromophenyl)-1,3-dioxolane affording compound **25**. The dioxolane group was converted to aldehyde through a treatment with a mixture of water/acetone under microwave irradiation [33]. The obtained aldehyde was used in the following reductive amination reaction with 1-Boc-piperazine giving compound **26**. From this intermediate, the two final compounds **5g,h** were obtained after Boc deprotection and a dehydroxylation procedure involving H_3PO_2 and I_2 (**5h**) [34].

For the synthesis of **5k** (Scheme 3), aminoguanidine **27** was cyclized to triazole **28** by treatment with AcOH [35], then this compound was converted to the 2-methyl-[1,2,4]triazolo [1,5-*a*]pyrimidine-5,7-diol by treatment with diethyl malonate in the presence of NaOEt [36], afterward the resulting intermediate was converted to the dichloro-derivative **29** through a reaction conducted in POCl_3 [37,38]. Intermediate **29** was then submitted to an aromatic substitution with the benzhydrylamine **30** and subsequently treated with a methanolic solution of NaOMe under MW irradiation, to afford compound **31**. After deprotection of the Boc-group, the final compound **5k** was isolated. Amine **30** was in turn prepared by treatment of ketone **32** (obtained as previously reported [24,25]) with hydroxylamine and successive reduction of the oxime with Zn in acidic medium.



Scheme 3. Reagents and Conditions: a) AcOH, toluene, 110 °C, 12 h; b) diethyl malonate, EtONa, EtOH, 0–80 °C, 12 h; c) POCl_3 , 110 °C, 12 h; d) EtOH, 25 °C, 12 h; e) NaOMe, MeOH, 100 W, 85 °C, 30 min; f) 1 N HCl in MeOH, 40 °C, 30 min; g) $\text{NH}_2\text{OH}\cdot\text{HCl}$, BaCO_3 , MeOH, 65 °C, 12 h; h) Zn, AcOH, NH_4Cl , 50 °C, 12 h.

The synthesis of the dimeric derivative **5m** is reported in Scheme 4. Alcohol **14** was oxidized with MnO₂ to the corresponding ketone, and upon deprotection of the silyl group, intermediate **33** was obtained. Compound **33** was then reacted with ethylene glycol dimesylate in the presence of sodium hydride. The monoalkylated derivative **34** was the major product of the reaction, while only traces of **35** were collected from the reaction mixture. The reaction between **34** and another equivalent of **33** afforded the bis-alkylated-derivative **35** in reasonable yield. Compound **5m** was finally obtained from **35** through chlorination, reaction with 7-chloro-4-aminoquinoline and *N*-Boc deprotection.

3. Results and structure-activity relationship (SAR) analysis

All synthesized compounds were evaluated for their *in vitro* antiplasmodial activity against the CQ-S strain D10 (which carries PfCRT^{3D7}) and the CQ-R resistant strain W2 (which carries PfCRT^{Dd2}) and for their ability to inhibit the PfCRT^{Dd2}-mediated transport of CQ (Table 1 and Fig. 2). *P. falciparum* viability was assessed using the activity of the parasite lactate hydrogenase as a marker, and inhibitory activity against PfCRT^{Dd2} was assessed in the *Xenopus* oocyte system. A subset of 15 compounds were screened for the ability to inhibit the transport of [³H]CQ via PfCRT^{Dd2} when present at 100 μM in the extracellular solution. Treatments containing 100 μM of a known inhibitor of PfCRT^{Dd2} – VP, chlorpheniramine (CP), or PQ – were included for comparison, and non-expressing oocytes were used as a negative control. In all cases, the lack of an effect in the non-expressing oocytes indicated that none of the compounds affect the simple diffusion of [³H]CQ into the oocytes (Fig. 2A). Beginning with the two reference compounds **4a,b**, we explored small modifications to their chemical structures to understand the key substitutions of our molecules necessary for the inhibition of PfCRT^{Dd2}. First, we verified the importance of the piperazine nitrogen atoms by isosteric replacement. Removal of the distal nitrogen gave rise to the isosteric piperidines **5a,b** or pyrrolidines **5c,d** through ring contraction. In all four cases, a reduction in the ability to inhibit PfCRT^{Dd2} was observed, but this effect was more evident with the piperidines (**5a,b**). Regarding the antiplasmodial activity, only modest changes in the IC₅₀ values against CQ-S and CQ-R strains were observed, with compounds **5c,d** exhibiting the lowest IC₅₀ values (27 and 22 nM, respectively) against the CQ-R strain. Comparisons between **5a,b** and **5c,d** revealed that the position of the chloride on the benzene ring did not affect inhibitory activity against PfCRT^{Dd2}. The replacement of the *m*-Cl with a *m*-OMe yielded compound **5e**, which inhibited PfCRT^{Dd2} to a similar extent as compounds **4a,b** and produced IC₅₀


values of 40 and 75 nM against the CQ-S and CQ-R strains, respectively. Since the phenolic analog **5f** showed a marked decrease in antiplasmodial activity, especially against the CQ-R strain (IC₅₀ of 475 nM), coupled with a moderate cross-resistance to CQ, its activity against PfCRT^{Dd2} was not evaluated.

To confirm the importance of the 4-aminoquinoline moiety on biological activity, a further set of compounds (**5g,h** and **6c,h,i**) was designed, synthesized, and tested for inhibitory activity against PfCRT^{Dd2}-mediated transport and *P. falciparum* growth. Compounds **6c,h,i** lack the 4-aminoquinoline moiety, whereas compounds **5g,h** lack the exocyclic nitrogen – which affects both the distance of the endocyclic quinoline nitrogen from the benzhydryl system and the basicity of the resulting quinoline. All of these compounds exhibited reduced activity against PfCRT^{Dd2} (relative to **4a,b**) and a substantial decrease in antiplasmodial activity against both the CQ-R and CQ-S strains. Compounds **6c,h,i** were the weakest inhibitors of PfCRT^{Dd2}-mediated CQ transport (inhibition of only 22–43% when present at 100 μM). These results confirmed the importance of the 4-aminoquinoline moiety and of its basicity to get a potent antiplasmodial activity and for inhibitory activity against PfCRT^{Dd2}.

Dimers of **4a** were also synthesized in an attempt to increase the inhibitory activity against PfCRT^{Dd2} [29]. Two different approaches were used to obtain those compounds: (i) the piperazine moiety was used as a dimerizing unit to produce compound **5l**; (ii) an ethyl glycol linker was used to connect two piperazine moieties, yielding compound **5m**. However, when compared with **4a**, both **5l** and **5m** exhibited reduced inhibitory activities against PfCRT^{Dd2} that could be ascribed to a non-correct orientation of the quinoline/protonatable chain moieties in the transporter induced by the linkers.

Interestingly, the derivatives bearing the 6-methoxy-8-aminoquinoline system characteristic of primaquine (compounds **5i,j**) retained appreciable activity against PfCRT^{Dd2} (~65% inhibition at 100 μM), whilst also exhibiting poor antiplasmodial activity, which is slightly higher than PQ. The final modification to the quinoline group was the substitution of the 6-methoxy-8-aminoquinoline moiety with a bioisosteric heterocycle (**5k**). PQ and its metabolic derivatives have an important role in the toxicity associated with this drug. Indeed, PQ and several of its metabolites, the most representative of which is 5-hydroxyprimaquine, induce the formation of methemoglobinemia at a rate and extension higher than usual, leading to the occurrence of hemolytic anemia [39]. Based on these observations, we replaced the quinoline group of **5i,j** with a triazolopyrimidine (TZP) as a bioisostere of the quinoline moiety of CQ [36,40–43]. Relative to compounds **5i,j**, **5k** was considerably more potent against the CQ-R strain, with a >10-fold reduction in the IC₅₀ (920 nM), but showed a similar level of activity against the CQ-S strain (3.70 μM). Furthermore, amongst the compounds tested in this study, **5k** emerged as the most potent inhibitor of CQ transport via PfCRT^{Dd2} (~98% inhibition at 100 μM and an IC₅₀ of 12.5 μM).

The poor antiplasmodial activity of the primaquine derivatives **5i,j** against asexual blood-stage *P. falciparum* parasites can be readily explained by the mode of action of PQ and its derivative, which target exoerythrocytic forms of the parasites such as gametocytes and hepatic schizonts via a P450-dependent bioactivation mechanism [44]. On the other hand, metabolic and/or non-enzymatic formation of PQ hydroxylated metabolites also play an important role in the toxicity of this drug [45]. Based on the above datasets, we sought to measure the activity of our PQ analogues against the exoerythrocytic forms of *Plasmodium*. A preliminary evaluation of the cytotoxicity of compounds **5i-k** revealed that **5i,j** exhibited a moderate level of cytotoxicity in the NIH3T3 cell line (TC₅₀ = 19 and 28 μM, respectively), whereas compound **5k** produced a TC₅₀ value lower than 3.5 μM. Hence, only compounds **5i,j** were progressed to assays with exoerythrocytic forms of *Plasmodium*.



Scheme 4. Reagents and Conditions: a) MnO₂, DCE, 80 °C, 6 h; b) TBAF, THF, 2 h, 25 °C; c) ethylene glycol dimesylate, NaH, DMF, 2 h, 80 °C; d) **33**, NaH, DMF, 2 h, 80 °C; e) NaBH₄, THF, 12 h, 25 °C; f) SOCl₂, 3 h, 80 °C; g) 4-amino-7-chloroquinoline, TEA, CH₃CN, 12 h, 80 °C; h) 1 N HCl in MeOH, 40 °C, 30 min.




Fig. 2. Effect of compounds **5a-m** and **6c,h,i** on the PfCRT^{Dd2}-mediated transport of CQ into *Xenopus* oocytes. **(A)** The uptake of [³H]CQ into non-expressing oocytes (white bars) and oocytes expressing PfCRT^{Dd2} (grey bars) was measured in the absence or presence of 100 μM of the test compound. The reference drugs were VP, CP, and PQ, all of which partially reverse CQ resistance *in vitro* by inhibiting the transport of CQ via PfCRT^{Dd2} [14,17]. The component of transport attributable to PfCRT^{Dd2} (i.e. PfCRT-mediated transport) was calculated by subtracting the level of uptake measured in non-expressing oocytes from that measured in oocytes expressing PfCRT^{Dd2} (see Fig. S1). Within each experiment, measurements were made from 10 oocytes per treatment and uptake was expressed relative to that measured in the PfCRT^{Dd2}-expressing oocytes under control conditions. The data are the mean of $n = 3-11$ independent experiments (each yielding similar results and overlaid as individual data points) and are shown \pm s.e.m. The grey asterisks denote a significant difference (*** $P < 0.001$, ** $P < 0.01$, and * $P < 0.005$; one-way ANOVA) in [³H]CQ accumulation between the control PfCRT^{Dd2} treatment and that measured in the presence of a test compound. Note that non-expressing oocytes take up [³H]CQ to a low level via simple diffusion of the neutral species of the drug; this represents the “background” level of CQ accumulation in oocytes [7]. The concentration-dependence of the effects of **5i** (**B**), **5j** (**C**), **5k** (**D**), and **5l** (**E**) on [³H]CQ uptake into oocytes expressing PfCRT^{Dd2} (see Fig. S1), PfCRT^{Dd2}-mediated transport (grey circles) was calculated by subtracting the level of uptake measured in non-expressing oocytes from that measured in oocytes expressing PfCRT^{Dd2}. The IC_{50} s derived from these data were obtained by a least-squares fit of the equation $Y = Y_{min} + [(Y_{max} - Y_{min}) / (1 + ([inhibitor] / IC_{50})^C)]$, where Y is the component of CQ uptake attributable to PfCRT^{Dd2}, Y_{min} and Y_{max} are the minimum and maximum values of Y , and C is a constant. Uptake is shown as the mean \pm s.e.m. from four (D and E) or six (B and C) independent experiments, within which measurements were made from 10 oocytes per treatment. Where not shown, error bars fall within the symbols.

3.1. *In vitro* evaluation of 5i and 5j against liver-stage parasites

Since PQ is the most important commercially available drug against the liver-stage of malaria, the PQ derivatives **5i** and **5j** were also tested against the liver-stage of *P. berghei*. Infected HepG2 cells were treated from 2 hpi onwards with different doses of PQ, **5i** or **5j**. At 48 hpi, parasite number (Fig. 3A) and size (Fig. 3B) were evaluated by automated microscopy. All the three drugs tested showed a

dose-response effect on the number of parasites. PQ was the least active (8 μM) to reduce the parasite numbers to about 50%. Compound **5i** reached this level at doses as low as 0.5 μM and compound **5j** even lower at 0.125 μM . Not only the number of parasites was reduced but also their size. Whereas PQ reduced the average parasite size to about half at 2 μM , compound **5i** showed a 50% reduction at 125 nM, and compound **5j** at 62.5 nM. These data demonstrate that the two PQ derivatives, compared with PQ, are




Fig. 3. Effects of compounds **5i** and **5j** on liver-stage growth and development compared to primaquine. HepG2 cells infected with mCherry expressing *Plasmodium berghei* sporozoites were exposed to different drug concentrations from 2 hpi. At 48 h the cells were fixed, and parasite size and count were evaluated by automated microscopy (INCell analyzer 2000, GE healthcare). The dotted red line indicates the host cell growth inhibiting concentration. DMSO was used as solvent control at the highest concentration used (e.g. for **5i**, same as for 8 µM concentration). In A) mean parasite numbers (6 replicates) with SD are shown for the individual compound concentrations. In B) median parasite sizes with interquartile range are shown for each concentration. The number of parasite size measurements were limited to 100 parasites for illustrative purposes. Statistical evaluations (One-way ANOVA with Dunnett's multiple comparisons) were done using Prism 8 (GraphPad) (ns: not significant, **: P < 0.01, ****: P < 0.0001).

more potent inhibitors against liver-stage parasites of *P. berghei*.

3.2. In vivo evaluation of **5i** and **5j** as transmission blocking compounds

The effects of the PQ analogues **5i** and **5j** on transmissible stages of *Plasmodium* were assessed with the murine malaria parasite *P. berghei* (ANKA strain GFP-con) using BALB/c mice and *Anopheles stephensi* mosquitoes. Neither **5i** nor **5j** showed any impact on transmissible stages. Mosquitoes fed on gametocytaemic mice, previously treated with **5i** or **5j** at 10 µmol/kg resulted in being highly infected (Fig. 4). Mean oocyst numbers amounted to 454 in the **5i** group and 491 in **5j** treated mosquitoes. For comparison, a similarly high number of oocysts (357) was counted in solvent control mosquitoes whereas in the positive reference group, in which mice were treated with PQ at the same dosage (10 µmol/kg), the mean oocyst number was markedly decreased (17). Since experimental mice have received 2 treatments, the first on day 3 of infection at the moment of gametocyte maturation and the second on day 4 just 1.5 h before mosquito feeding, it can be concluded that **5i** and **5j** did not interfere neither with gametocytes nor with the development of early sporogonic stages in the mosquito midgut.

4. Conclusions

In this work we describe the discovery of a new library of antimalarial compounds endowed with an inhibitory activity against the Dd2 isoform of PfCRT. The synthesis of compounds **5a,b,i-l** was performed by applying procedures previously described by us, while the other final products were obtained




Fig. 4. Effects of **5i** and **5j** on transmissible stages of *P. berghei* in vivo. Gametocytaemic mice were treated with **5i** and **5j** at 10 µmol/kg twice (3 days after mouse infection and 1.5 h before mosquito feeds). PQ (10 µmol/kg) served as positive reference and PBS as solvent control. For each treatment 3 mouse - mosquito cage replicates were performed. Oocyst numbers were assessed on 20–30 mosquitoes (minimum 8) of each replicate cage by gut dissection on day 8 after infection. Columns represent geometric mean numbers of oocysts from positive mosquitoes of 3 cages per treatment. Vertical bars depict the SD. Mean oocyst numbers of the **5i** and **5j** treatments were not different from solvent control replicates (2-tailed *t*-test: **5i** vs control: *p* = 0.2024; **5j** versus control: *p* = 0.2118).

following newly developed synthetic schemes. The SAR analysis revealed that the presence of the 4-aminoquinoline moiety is crucial for retaining strong potency against both CQ-S and CQ-R strains of *P. falciparum* (**5a-f**). *N*-methylenpyrrolidine as a basic substituent yielded the most potent activity against the

P. falciparum strains. No particular differences in potency were highlighted by *p*- or *m*-substitution on the aromatic moiety. In this context, a chloride or a methoxy group generated the compounds with the highest activities. Among these compounds, **5d** and **5e** exhibited potent inhibition of CQ transport via PfCRT^{Dd2}. However, within all of the synthesized products, **5k** was the most potent against PfCRT^{Dd2}, and this property correlates with the marked increase in its cytotoxicity against the CQ-R *P. falciparum* strain (IC₅₀ = 0.92 μM) versus its activity against the CQ-S strain (IC₅₀ = 3.70 μM). Compounds **5l** and **5m**, which are dimers of compound **4a**, were also synthesized in an attempt to increase the inhibitory activity against PfCRT. However, when compared to **4a**, **5l** and **5m** exhibited reduced inhibitory and cytotoxicity profiles. Compounds **5i** and **5j**, linked to an 8-aminoquinoline moiety, showed a similar activity to their parent compound (PQ) against blood-stage parasites. Interestingly, in the *in vitro* assays, these compounds were up to 64 times more active against the liver-stage than PQ. These findings will be the subject of further studies aimed at defining their mode of action. These compounds showed an inhibitory activity against PfCRT in line with the other analogues described in this work. From the cytotoxicity assays against murine fibroblasts, compounds **5i** and **5j** showed a safe profile. Given that PQ has a cytotoxic action against the sexual stages of malaria, and that **5i** and **5j** were more active than PQ against the liver-stage parasites, we investigated their activity in an *in vivo* transmission blocking assay. Unfortunately, they did not interfere with the development of either gametocytes or the early sporogonic stages in the mosquito midgut. We believe that this work may pave the way for the development of potent antimalarial agents, active against liver- and blood-stage CQ-S and CQ-R parasites, that are also potent blockers of PfCRT. Additional optimization of these compounds may be useful to identify potential lead compounds for further biological investigation.

5. Experimental section

5.1. General information

Unless otherwise specified, materials were purchased from commercial suppliers and used without further purification. Reaction progress was monitored by TLC using silica gel 60 F254 (0.040–0.063 mm) with detection by UV. Silica gel 60 (0.040–0.063 mm) was used for column chromatography. ¹H NMR and ¹³C NMR spectra were recorded on a Varian 300 MHz spectrometer or a Bruker 400 MHz spectrometer by using the residual signal of the deuterated solvent as internal standard. Splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q) and broad (br); the values of chemical shifts (δ) are given in ppm and coupling constants (*J*) in Hertz (Hz). HPLC analysis were performed with a Shimadzu Prominence apparatus equipped with a scanning absorbance UV-VIS detector (Diode Array SPD-M20A) also equipped with a thermostatic chamber or with Agilent 1100 Series equipped with UV-VIS detector or LaPrep P130 apparatus using a P311 UV detector. Purity of final products (>95%) was determined by analytical HPLC Merck Purospher® STAR RP-18e (5 μm) LiChro-CART® 250-4 column; detection at 254 nm; flow rate = 1.0 mL/min; mobile phase A, 0.01% TFA (v/v) in water; mobile B, MeCN; gradient, 90/10–10/90 A/B in 20 min. The gradient was optimized based on the compound polarity. Unless otherwise indicated, retention times (RT) refer to the above-described conditions. ESI-MS spectra were performed by an Agilent 1100 Series LC/MSD spectrometer. Melting points were detected by a BÜCHI melting point B-450 and reported as °C. The yields are referred to purified products and are not optimized. All moisture-sensitive reactions were performed under argon atmosphere using oven-dried

glassware and anhydrous solvents.

5.2. Chemistry

5.2.1. 1-(4-(Chloro(4-chlorophenyl)methyl)benzyl)piperidine (**7a**)

To a solution of **6a** (0.20 g, 0.63 mmol) in dry DCM (10 mL) SOCl₂ (274 μL, 3.78 mmol) was added and the reaction was stirred at 45 °C for 1 h. The solvent was evaporated and crude **7a** (0.21 g, quantitative yield) was used in the next step without further purifications. ¹H NMR: (300 MHz, CDCl₃) δ 7.66 (d, 2H, *J* = 7.9 Hz), 7.43 (d, 2H, *J* = 7.9 Hz), 7.29–7.14 (m, 4H), 6.06 (s, 1H), 4.11 (s, 2H), 3.41 (d, 2H, *J* = 11 Hz) 2.64–2.53 (m, 2H), 2.34–2.25 (m, 2H), 1.88–1.77 (m, 2H), 1.37–1.32 (m, 2H). ESI MS *m/z*: [M + H]⁺ 334.

5.2.2. 1-(4-(Chloro(3-chlorophenyl)methyl)benzyl)piperidine (**7b**)

Starting from **6b** (0.18 g, 0.60 mmol) the title compound was prepared following the procedure of **6a**. Crude was used in the next reaction without any further purification. **7b** (0.20 g, quantitative yield) was obtained as a brown oil. ¹H NMR: (300 MHz, CDCl₃) δ 7.68–7.65 (m, 2H), 7.38–7.09 (m, 6H), 6.00 (s, 1H), 4.15 (s, 2H), 3.35 (br, 2H), 2.72–2.67 (m, 2H), 2.18–2.12 (m, 2H), 1.77–1.72 (m, 2H), 1.36–1.31 (m, 2H). ESI MS *m/z*: [M + H]⁺ 334.

5.2.3. 1-(4-(Chloro(4-chlorophenyl)methyl)phenethyl)pyrrolidine (**7c**)

Starting from **6c** (0.18 g, 0.60 mmol) the title compound was prepared following the procedure of **7a**. Crude was used in the next reaction without any further purification. **7c** (0.20 g, quantitative yield) was obtained as a brown oil. ¹H NMR (300 MHz, CDCl₃) δ 7.38–7.29 (m, 6H), 7.28–7.22 (m, 2H), 6.05 (s, 1H), 3.81 (br, 2H), 3.24 (s, 4H), 2.78 (br, 2H), 2.24 (br, 2H), 2.06 (br, 2H). MS (ESI) *m/z* 334 [M+H]⁺.

5.2.4. 1-(4-(Chloro(3-chlorophenyl)methyl)phenethyl)pyrrolidine (**7d**)

Starting from **6d** (0.18 g, 0.60 mmol) the title compound was prepared following the procedure of **7a**. Crude was used in the next reaction without any further purification. **7d** (0.19 g, quantitative yield) was obtained as a brown oil. ¹H NMR (300 MHz, CDCl₃) δ 7.44–6.98 (m, 8H), 5.99 (s, 1H), 3.73 (br, 2H), 3.21 (br, 4H), 2.81 (br, 2H), 2.26–1.84 (m, 4H). MS (ESI) *m/z* 334 [M+H]⁺.

5.2.5. 7-Chloro-N-((4-chlorophenyl)(4-(piperidin-1-ylmethyl)phenyl)methyl)quinolin-4-amine (**5a**)

To a solution of **7a** (0.84 g, 2.52 mmol) in MeCN (5 mL) TEA (1.05 mL, 7.56 mmol) and 4-Amino-7-chloroquinoline (0.54 g, 3.024 mmol) were added. The reaction was stirred at 80 °C for 12 h, then the solvent was evaporated, water was added, and the mixture was extracted with DCM. The crude material was purified by chromatography on silica gel (2% of MeOH in DCM) obtaining **5a** (0.406 g, 34%) as a white solid. ¹H NMR: (300 MHz, CDCl₃) δ 8.40 (d, 1H, *J* = 5.3 Hz), 7.95 (d, 1H, *J* = 2.1 Hz), 7.74 (d, 1H, *J* = 9.1 Hz), 7.36–7.23 (m, 8H), 6.22 (d, 1H, *J* = 5.6 Hz), 5.69 (d, 1H, *J* = 4.1 Hz), 5.50 (d, 1H, *J* = 4.4 Hz), 3.44 (s, 2H), 2.36 (br, 4H), 1.60–1.52 (m, 4H), 1.44–1.42 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 152.0, 149.0, 148.2, 139.3, 135.0, 133.7, 130.0, 129.2, 129.0, 128.6, 127.3, 125.7, 120.8, 117.1, 110.0, 101.3, 63.3, 61.5, 54.5, 25.8, 24.3; HRMS-ESI *m/z*: calcd for C₂₈H₂₈Cl₂N₃⁺ [M+H]⁺: 476.1655; found: 476.1651; ESI MS *m/z*: 476 [M + H]⁺ m.p.: 200–202 °C; HPCL RT: 11.2 min.

5.2.6. 7-Chloro-N-((3-chlorophenyl)(4-(piperidin-1-ylmethyl)phenyl)methyl)quinolin-4-amine (**5b**)

Starting from **7c** (0.12 g, 0.36 mmol) the title compound was prepared following the procedure of **5a**. The crude residue was purified by flash column chromatography on alumina (5% MeOH in

DCM) obtaining **5c** (0.50 g, 29%) as a white solid. ^1H NMR: (300 MHz, CDCl_3) δ 8.44 (d, 1H, $J = 5.3$ Hz), 7.98 (d, 1H, $J = 2.3$ Hz), 7.73 (d, 1H, $J = 8.8$ Hz) 7.40–7.25 (m, 8H), 6.24 (d, 1H, $J = 5.3$ Hz), 5.68 (d, 1H, $J = 4.4$ Hz), 5.42 (d, 1H, $J = 4.1$ Hz), 3.46 (s, 2H), 2.38 (br, 4H), 1.61–1.54 (m, 4H), 1.47–1.44 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 151.9, 149.0, 148.2, 142.8, 139.2, 138.4, 135.0 (2C), 130.4, 130.2, 129.0, 128.2, 127.4, 127.3, 125.7, 125.3, 120.9, 117.1, 101.3, 63.1, 61.7, 54.5, 25.7, 24.1; HRMS-ESI m/z : calcd for $\text{C}_{28}\text{H}_{28}\text{Cl}_2\text{N}_3^+$ $[\text{M}+\text{H}]^+$: 476.1655; found: 476.1660; ESI MS m/z : 476 $[\text{M} + \text{H}]^+$; Melting point 204–206 °C; HPLC RT: 11.0 min.

5.2.7. 7-Chloro-*N*-((4-chlorophenyl)(4-(2-(pyrrolidin-1-yl)ethyl)phenyl)methyl)quinolin-4-amine (**5c**)

Starting from **7c** (0.20 g, 0.6 mmol) the title compound was prepared following the procedure of **5a**. The crude residue was purified by flash column chromatography on alumina (5% MeOH in DCM) obtaining **5c** (0.05 g, 18%) as a pale yellow solid. ^1H NMR (300 MHz, CDCl_3) δ 8.41 (d, $J = 5.2$ Hz, 1H), 7.96 (s, 1H), 7.71 (d, $J = 8.9$ Hz, 1H), 7.42–7.12 (m, 9H), 6.21 (d, $J = 5.2$ Hz, 1H), 5.67 (d, $J = 3.8$ Hz, 1H), 5.42 (d, $J = 3.1$ Hz, 1H), 2.93–2.76 (m, 2H), 2.76–2.62 (m, 2H), 2.57 (br, 4H), 1.80 (br, 4H); ^{13}C NMR (75 MHz, CDCl_3) δ 151.9, 149.0, 148.2, 140.3, 139.3, 138.5, 135.0, 133.7, 129.5, 129.2, 128.6, 127.6, 125.7, 121.0, 117.1, 101.4, 61.4, 57.9, 54.1, 35.0, 23.5; MS (ESI) m/z 476 $[\text{M}+\text{H}]^+$; HRMS-ESI m/z : calcd for $\text{C}_{28}\text{H}_{28}\text{Cl}_2\text{N}_3^+$ $[\text{M}+\text{H}]^+$: 476.1655; found: 476.1663; HPLC RT: 11.4 min.

5.2.8. 7-Chloro-*N*-((3-chlorophenyl)(4-(2-(pyrrolidin-1-yl)ethyl)phenyl)methyl)quinolin-4-amine (**5d**)

Starting from **7d** (0.191 g, 0.6 mmol) the title compound was prepared following the procedure of **5a**. The crude residue was purified by flash column chromatography on alumina (5% MeOH in DCM) obtaining **5d** (0.117 g, 43%) as a pale-yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.39 (d, $J = 5.1$ Hz, 1H), 7.96 (s, 1H), 7.70 (d, $J = 8.9$ Hz, 1H), 7.44–7.29 (m, 2H), 7.29–7.04 (m, 7H), 6.21 (d, $J = 5.2$ Hz, 1H), 5.65 (d, $J = 3.9$ Hz, 1H), 5.42 (d, $J = 3.6$ Hz, 1H), 2.87–2.74 (m, $J = 8.9$ Hz, 2H), 2.74–2.63 (m, 2H), 2.56 (br, 4H), 1.78 (br, 4H); ^{13}C NMR (75 MHz, CDCl_3) δ 151.4, 148.6, 148.5, 142.7, 139.0, 137.6, 135.2, 135.0, 130.4, 129.5, 128.4, 128.2, 128.1, 127.4, 125.8, 125.5, 121.5, 117.4, 101.2, 61.5, 57.0, 53.9, 32.8, 23.4; MS (ESI) m/z 476 $[\text{M}+\text{H}]^+$; HRMS-ESI m/z : calcd for $\text{C}_{28}\text{H}_{28}\text{Cl}_2\text{N}_3^+$ $[\text{M}+\text{H}]^+$: 476.1655; found: 476.1660; HPLC RT: 11.1 min.

5.2.9. 3-((*tert*-Butyldiphenylsilyloxy)benzaldehyde (**10**)

To a solution of **8** (2.0 g, 16.4 mmol) in dry THF (100 mL) cooled at 0 °C, imidazole (1.3 g, 19.7 mmol) and TBDPSCI (5.1 mL, 19.7 mmol) were added. Reaction was stirred at 25 °C for 12 h, then water was added, solvent was evaporated, and the residue was extracted with DCM. The combined organic layers were dried over Na_2SO_4 and concentrated *in vacuo*. The crude material was purified by chromatography on silica gel (5% EtOAc in PetEt) obtaining **10** (5.3 g, 90%) as colorless oil. ^1H NMR: (300 MHz, CDCl_3) δ 9.82 (s, 1H), 7.76–7.66 (m, 4H), 7.47–7.34 (m, 7H), 7.30–7.27 (m, 1H), 7.24–7.18 (m, 1H), 6.99–6.91 (m, 1H), 1.12 (s, 9H); MS (ESI) m/z : 361 $[\text{M} + \text{H}]^+$.

5.2.10. 4-(1,3-Dioxolan-2-yl)phenyl(3-methoxyphenyl)methanol (**11**)

Starting from **9** (585 μL , 4.8 mmol) and 2-(4-bromophenyl)-1,3-dioxolane (1.0 g, 4.4 mmol) the title compound was prepared following the procedure of **25**. The crude residue was purified by flash column chromatography on silica gel (25% EtOAc in PetEt) obtaining **11** (0.505 g, 44%) as colorless oil. ^1H NMR: (300 MHz, Acetone) δ 7.50–7.34 (m, 4H, 4H), 7.20 (t, $J = 7.9$ Hz, 1H), 7.03 (s, 1H), 6.96 (d, $J = 6.3$ Hz, 1H), 6.77 (dd, $J = 8.2, 2.6$ Hz, 1H), 5.81 (d, $J = 3.9$ Hz, 1H), 5.70 (s, 1H), 4.85 (d, $J = 3.9$ Hz, 1H), 4.18–3.87 (m, 4H), 3.76 (s, 3H); MS (ESI) m/z : 287 $[\text{M} + \text{H}]^+$.

5.2.11. 4-(1,3-Dioxolan-2-yl)phenyl(3-((*tert*-butyldiphenylsilyloxy)phenyl)methanol (**12**)

Starting from **10** (2.2 g, 6.0 mmol) and 2-(4-bromophenyl)-1,3-dioxolane (1.3 g, 5.4 mmol) the title compound was prepared following the procedure of **25**. The crude residue was purified by flash column chromatography on silica gel (25% EtOAc in PetEt) obtaining **12** (1.5 g, 54%) as colorless oil. ^1H NMR: (300 MHz, CDCl_3) δ 7.67 (d, $J = 6.7$ Hz, 4H), 7.49–7.30 (m, 8H), 7.19 (d, $J = 8.1$ Hz, 2H), 7.02 (t, $J = 7.9$ Hz, 1H), 6.82 (d, $J = 7.6$ Hz, 1H), 6.77 (s, 1H), 6.64 (d, $J = 9.5$ Hz, 1H), 5.79 (s, 1H), 5.62 (s, 1H), 4.16–3.97 (m, 4H), 1.08 (s, 9H); MS (ESI) m/z : 533 $[\text{M} + \text{Na}]^+$.

5.2.12. *tert*-Butyl 4-(4-(hydroxy(3-methoxyphenyl)methyl)benzyl)piperazine-1-carboxylate (**13**)

Step e: To a solution of **11** (0.40 g, 1.4 mmol) in THF (8 mL) a 1 N solution of HCl was added (4 mL). Mixture was stirred at 25 °C for 4 h; NaHCO_3 was added and THF was evaporated. Residue was extracted with EtOAc and the combined organic layers were dried over Na_2SO_4 and concentrated *in vacuo*; the crude residue was used in the next reaction without any further purification. Compound 4-(hydroxy(3-methoxyphenyl)methyl)benzaldehyde (0.38 g, quantitative yield) was obtained as a colorless oil. ^1H NMR: (300 MHz, CDCl_3) δ 9.91 (s, 1H), 7.80 (d, $J = 6.7$ Hz, 2H), 7.54 (d, $J = 8.1$ Hz, 2H), 7.24 (t, $J = 7.3$ Hz, 1H), 6.95–6.86 (m, 2H), 6.80 (d, $J = 7.5$ Hz, 1H), 5.81 (s, 1H), 3.75 (s, 3H), 3.06 (br, 1H); MS (ESI) m/z : 241 $[\text{M} - \text{H}]^-$.

Step f: Compound **13** was obtained starting from the above-obtained compound (0.35 g, 1.4 mmol) following the procedure used for **26g**. Crude compound was purified by chromatography on silica gel (40% PetEt in EtOAc) obtaining **13** (0.578 g, 89%) as a pale yellow oil. ^1H NMR: (300 MHz, CDCl_3) δ 7.35–7.11 (m, 5H), 6.91 (d, $J = 8.9$ Hz, 2H), 6.74 (s, 1H), 5.68 (s, 1H), 3.70 (s, 3H), 3.40 (s, 2H), 3.32 (br, 4H), 2.28 (br, 4H), 1.42 (s, 9H); MS (ESI) m/z : 413 $[\text{M} + \text{H}]^+$.

5.2.13. *tert*-Butyl 4-(4-((3-((*tert*-butyldiphenylsilyloxy)phenyl)(hydroxy)methyl)benzyl)piperazine-1-carboxylate (**14**)

Starting from **12** (1.5 g, 2.9 mmol) the title compound was prepared following the procedure of **13**. The crude residue was purified by flash column chromatography on silica gel (25% EtOAc in PetEt) obtaining **14** (1.5 g, 70%) as colorless oil. ^1H NMR: (300 MHz, CDCl_3) δ 7.72–7.62 (m, 4H), 7.47–7.28 (m, 6H), 7.24–7.10 (m, 4H), 7.04 (t, $J = 7.9$ Hz, 1H), 6.85 (d, $J = 7.2$ Hz, 1H), 6.79 (s, 1H), 6.66 (d, $J = 8.1$ Hz, 1H), 5.61 (s, 1H), 3.46 (s, 2H), 3.41 (br, 4H), 2.36 (br, 4H), 1.45 (s, 9H), 1.08 (s, 9H); MS (ESI) m/z : 637 $[\text{M} + \text{H}]^+$.

5.2.14. *tert*-Butyl 4-(4-(((7-chloroquinolin-4-yl)amino)(3-methoxyphenyl)methyl)benzyl)piperazine-1-carboxylate (**17**)

Step e: Starting from **13** (0.124 g, 0.3 mmol), **15** was prepared following the procedure used for compound **7a**. **15** (0.10 g, 76%) was obtained as a pale yellow oil and was used in the next step without any further purification. ^1H NMR: (300 MHz, CDCl_3) δ 7.41–7.28 (m, 4H), 7.26–7.14 (m, 1H), 7.05–6.96 (m, 2H), 6.84 (d, $J = 8.2$ Hz, 1H), 6.09 (s, 1H), 3.80 (s, 3H), 3.49 (s, 2H), 3.43 (br, 4H), 2.38 (br, 4H), 1.46 (s, 9H); MS (ESI) m/z : 431 $[\text{M} + \text{H}]^+$.

Starting from **15** (0.10 g, 0.2 mmol), the title compound **17** (0.034 g, 26%) was obtained following the procedure used for compound **5a**. **17** was obtained as a pale-yellow oil. ^1H NMR: (300 MHz, CDCl_3) δ 8.38 (d, $J = 5.3$ Hz, 1H), 7.93 (d, $J = 2.1$ Hz, 1H), 7.73 (d, $J = 9.0$ Hz, 1H), 7.37–7.19 (m, 6H), 6.93 (d, $J = 7.7$ Hz, 1H), 6.90–6.87 (m, 1H), 6.84–6.78 (m, 1H), 6.25 (d, $J = 5.4$ Hz, 1H), 5.67 (d, $J = 4.4$ Hz, 1H), 5.55 (d, $J = 4.5$ Hz, 1H), 3.73 (s, 3H), 3.47 (s, 2H), 3.40 (br, 4H), 2.36 (br, 4H), 1.43 (s, 9H); MS (ESI) m/z : 573 $[\text{M} + \text{H}]^+$.

5.2.15. *tert*-Butyl 4-(4-((3-((*tert*-butyldiphenylsilyloxy)phenyl)((7-chloroquinolin-4-yl)amino)methyl)benzyl)piperazine-1-carboxylate (**18**)

Starting from **14** (0.088 g, 0.1 mmol) the title compound was prepared following the procedure of **5a**. The crude residue was purified by flash column chromatography on silica gel (2% MeOH in DCM) obtaining **18** (0.035 g, 34%) as pale-yellow oil. $^1\text{H NMR}$: (300 MHz, CDCl_3): δ 8.36 (d, $J = 5.1$ Hz, 1H), 7.97 (s, 1H), 7.69–7.60 (m, 2H), 7.57–7.50 (m, 2H), 7.45–7.09 (m, 11H), 7.00 (d, $J = 7.0$ Hz, 2H), 6.84 (d, $J = 7.9$ Hz, 2H), 6.67 (s, 1H), 6.10 (d, $J = 5.4$ Hz, 1H), 5.44 (d, $J = 4.0$ Hz, 1H), 5.08 (d, $J = 4.0$ Hz, 1H), 3.46 (s, 2H), 3.43 (br, 4H), 2.36 (br, 4H), 1.46 (s, 9H), 1.04 (s, 9H); MS (ESI) m/z : 798 [M + H] $^+$.

5.2.16. 7-Chloro-*N*-((3-methoxyphenyl)(4-(piperazin-1-ylmethyl)phenyl)methyl)quinolin-4-amine (**5e**)

17 (0.085 g, 0.2 mmol) was dissolved in MeOH and a 1 M solution of HCl in MeOH was slowly added. The mixture was evaporated at 45 °C under vacuum. This procedure was repeated three times. **5e** was obtained as a colorless oil (0.07 g, quantitative yield). $^1\text{H NMR}$: (300 MHz, CDCl_3) δ 8.43 (d, $J = 5.3$ Hz, 1H), 7.98 (d, $J = 2.0$ Hz, 1H), 7.71 (d, $J = 9.0$ Hz, 2H), 7.43–7.26 (m, 5H), 7.01–6.79 (m, 3H), 6.27 (d, $J = 5.4$ Hz, 1H), 5.68 (d, $J = 4.3$ Hz, 1H), 5.40 (d, $J = 4.3$ Hz, 1H), 3.77 (s, 3H), 3.48 (s, 2H), 2.88 (br, 4H), 2.41 (br, 4H); $^{13}\text{C NMR}$: (75 MHz, CDCl_3) δ 159.1, 151.0, 148.0, 147.4, 141.6, 138.7, 137.1, 133.9, 129.1, 128.8, 127.9, 126.3, 124.5, 120.0, 118.5, 116.1, 112.4, 111.7, 100.2, 62.1, 61.0, 54.2, 53.3, 44.9; MS (ESI) m/z : 473 [M + H] $^+$; HRMS-ESI m/z : calcd for $\text{C}_{28}\text{H}_{30}\text{ClN}_4\text{O}^+$ [M+H] $^+$: 473.2103; found: 473.2110; HPLC RT: 8.9 min.

5.2.17. 3-(((7-Chloroquinolin-4-yl)amino)(4-(piperazin-1-ylmethyl)phenyl)methyl)phenol (**5f**)

Step g: To a solution of **18** (0.035 g, 0.04 mmol) in dry THF, cooled to 0 °C (5 mL) a 1 M solution of TBAF in THF (130 L, 0.1 mmol) was added. Reaction was allowed to reach 25 °C and stirred for 2 h. Water was added, THF was evaporated and residue was extracted with DCM and the combined organic layers were dried over Na_2SO_4 and concentrated *in vacuo*. Crude was purified by flash chromatography on silica gel (MeOH 3% in DCM). Compound *tert*-butyl 4-(4-(((7-chloroquinolin-4-yl)amino)(3-hydroxyphenyl)methyl)benzyl)piperazine-1-carboxylate (0.02 g, 81%) was obtained as pale yellow oil. $^1\text{H NMR}$: (300 MHz, CDCl_3) δ 8.20 (d, $J = 5.5$ Hz, 1H), 7.92 (d, $J = 2.0$ Hz, 1H), 7.54 (d, $J = 9.0$ Hz, 1H), 7.28 (s, 4H), 7.26 (d, $J = 0.6$ Hz, 1H), 7.25 (d, $J = 2.0$ Hz, 1H), 7.20 (t, $J = 7.8$ Hz, 1H), 6.90 (s, 1H), 6.82 (d, $J = 8.0$ Hz, 1H), 6.74 (d, $J = 7.8$ Hz, 1H), 6.15 (d, $J = 5.6$ Hz, 1H), 5.60 (d, $J = 4.3$ Hz, 1H), 5.48 (d, $J = 4.5$ Hz, 1H), 3.48 (s, 2H), 3.42 (br, 4H), 2.38 (br, 4H), 1.45 (s, 9H); MS (ESI) m/z : 559 [M + H] $^+$.

Step h: Starting from the above obtained compound (0.02 g, 0.04 mmol), the title compound was prepared following the procedure of **5e**. **5f** was obtained as a colorless oil (0.017 g, quantitative yield). $^1\text{H NMR}$: (300 MHz, CDCl_3) δ 8.26 (d, $J = 5.4$ Hz, 1H), 7.92 (d, $J = 2.1$ Hz, 1H), 7.59 (d, $J = 9.1$ Hz, 1H), 7.33–7.17 (m, 6H), 6.90–6.69 (m, 3H), 6.19 (d, $J = 5.6$ Hz, 1H), 5.63 (d, $J = 4.4$ Hz, 1H), 5.44 (d, $J = 4.5$ Hz, 1H), 3.44 (s, 2H), 2.84 (br, 4H), 2.38 (br, 4H); $^{13}\text{C NMR}$: (75 MHz, CDCl_3) δ 158.1, 151.5, 148.9, 148.3, 142.1, 140.1, 137.9, 135.3, 130.6, 130.2, 128.2, 127.7, 125.9, 121.1, 119.0, 117.0, 115.8, 114.1, 101.3, 63.2, 61.9, 54.1, 45.8; MS (ESI) m/z : 459 [M + H] $^+$. HPLC RT: 7.3 min.

5.2.18. *tert*-Butyl 4-(4-((3-chlorophenyl)((6-methoxyquinolin-8-yl)amino)methyl)benzyl)piperazine-1-carboxylate (**21**)

To a solution of **20** (0.104 g, 0.2 mmol) in dry CH_3CN (5 mL) DIPEA (110 μL , 0.6 mmol) and **SI19** (0.05 g, 0.3 mmol) were added. The resulting solution was stirred at 80 °C for 12 h, then water was added, solvent was evaporated, and residue was extracted with DCM. The combined organic layers were dried over Na_2SO_4 and concentrated *in vacuo*. Crude compound **21** was purified by

chromatography on silica gel (50% EtOAc in PetEt), and it was obtained as a pale-yellow oil (0.05 g, 30%). $^1\text{H NMR}$: (300 MHz, CDCl_3) δ 8.54 (d, $J = 4.2$ Hz, 1H), 7.94 (d, $J = 8.3$ Hz, 1H), 7.41 (s, 1H), 7.36–7.22 (m, 8H), 6.73 (d, $J = 4.8$ Hz, 1H), 6.38 (d, $J = 2.3$ Hz, 1H), 6.10 (d, $J = 2.3$ Hz, 1H), 5.59 (d, $J = 4.9$ Hz, 1H), 3.77 (s, 3H), 3.48 (s, 2H), 3.43 (br, 4H), 2.38 (br, 4H), 1.45 (s, 9H); MS (ESI) m/z : 573 [M + H] $^+$.

5.2.19. *N*-((3-Chlorophenyl)(4-(piperazin-1-ylmethyl)phenyl)methyl)-6-methoxyquinolin-8-amine (**5i**)

Compound **5i** was obtained starting from **21** (0.017 g, 0.03 mmol) following the procedure described before to obtain compound **5e**. Crude **5i** was purified by chromatography on silica gel (3% MeOH in DCM) and was obtained as a pale yellow oil (0.012 g, 86%). $^1\text{H NMR}$: (300 MHz, CDCl_3) δ 8.54 (d, $J = 4.1$ Hz, 1H), 7.94 (d, $J = 8.3$ Hz, 1H), 7.41 (s, 1H), 7.39–7.16 (m, 8H), 6.73 (d, $J = 4.8$ Hz, 1H), 6.38 (d, $J = 2.1$ Hz, 1H), 6.11 (d, $J = 2.0$ Hz, 1H), 5.59 (d, $J = 4.8$ Hz, 1H), 3.80 (s, 3H), 3.46 (s, 2H), 2.88 (br, 4H), 2.41 (br, 4H); $^{13}\text{C NMR}$: (75 MHz, CDCl_3) δ 159.3, 144.9, 144.8, 144.7, 140.9, 137.9, 135.6, 135.0, 134.9, 130.3, 129.9, 129.8 (2C), 127.8, 127.7, 125.8, 122.2, 99.0, 93.2, 63.5, 62.3, 55.4, 54.6, 46.2; MS (ESI) m/z : 473 [M + H] $^+$. HPLC (gradient, 95/5–55/45 A/B in 12 min) RT: 9.5 min.

5.2.20. *N*-((3-Chlorophenyl)(4-(pyrrolidin-1-ylmethyl)phenyl)methyl)-6-methoxyquinolin-8-amine (**5j**)

Starting from **19** (0.10 g, 0.3 mmol) and **SI19** (0.065 g, 0.4 mmol) the title compound was prepared following the procedure of **21**. The crude material was purified by flash chromatography on silica gel (2% MeOH in DCM) to give **5j** as a pale yellow oil (0.091 g, 50%). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.54 (d, $J = 4.2$ Hz, 1H), 7.94 (d, $J = 8.3$ Hz, 1H), 7.51–7.13 (m, 8H), 6.73 (d, $J = 4.8$ Hz, 1H), 6.38 (s, 1H), 6.11 (s, 1H), 5.59 (d, $J = 4.9$ Hz, 1H), 3.80 (s, 3H), 3.60 (s, 2H), 2.51 (br, 4H), 1.78 (br, 5H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 159.3, 144.9, 144.8, 144.8, 140.7, 139.2, 137.5, 135.6, 135.0, 134.9, 130.3, 129.8, 129.7, 127.8, 127.7, 125.8, 122.2, 99.0, 93.2, 62.3, 60.6, 55.4, 54.5, 23.7; ESI MS m/z : 458 [M + H] $^+$; HRMS-ESI m/z : calcd for $\text{C}_{28}\text{H}_{29}\text{ClN}_3\text{O}^+$ [M+H] $^+$: 458.1994; found: 458.1998; HPLC RT: 14.6 min.

5.2.21. 7-Chloroquinoline-4-carbaldehyde (**23**)

To a solution of 4,7-dichloroquinoline (1.5 g, 7.6 mmol) in dry Et_2O , [1,2-bis(diphenylphosphino)ethane]dichloronickel (II) (0.04 g, 0.07 mmol) was added. Suspension was cooled to 0 °C and a 3.0 M solution of methylmagnesium bromide (2.6 mL, 7.6 mmol) in Et_2O was added. Reaction was stirred at 25 °C for 12 h. A saturated solution of NH_4Cl was added to the reaction and mixture was extracted with Et_2O . The combined organic layers were dried over Na_2SO_4 and concentrated *in vacuo*. The crude material was purified by chromatography on silica gel (5% of EtOAc in PetEt) obtaining 7-chloro-4-methylquinoline (1.9 g, 70%) as a low melting point white solid. $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.77 (d, $J = 4.4$ Hz, 1H), 8.10 (s, 1H), 7.93 (d, $J = 8.9$ Hz, 1H), 7.52 (d, $J = 8.9$ Hz, 1H), 7.23 (d, $J = 4.5$ Hz, 1H), 2.70 (s, 3H); MS (ESI) m/z 178 [M+H] $^+$.

To a solution of 7-chloro-4-methylquinoline (0.50 g, 2.8 mmol) in DMSO (15 mL) TFA (274 μL , 3.6 mmol), *tert*-butyliodide (342 μL , 2.9 mmol), iodine (0.75 g, 3.0 mmol) and FeCl_2 (0.13 g, 0.7 mmol) were added in this order and mixture was heated at 80 °C for 6 h. Thereafter a saturated solution of $\text{Na}_2\text{S}_2\text{O}_3$ and a saturated solution of NaHCO_3 were added. Mixture was extracted with EtOAc and the combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*. The crude material was purified by chromatography on silica gel (20% of EtOAc in PetEt) obtaining **23** (0.468 g, 87%) as a white solid. $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 10.45 (s, 1H), 9.21 (d, $J = 4.2$ Hz, 1H), 9.01 (d, $J = 9.1$ Hz, 1H), 8.22 (d, $J = 2.1$ Hz, 1H), 7.79 (d, $J = 4.2$ Hz, 1H), 7.68 (dd, $J = 9.1, 2.1$ Hz, 1H); MS (ESI) m/z 192 [M+H] $^+$.

5.2.22. (4-Chlorophenyl)(7-chloroquinolin-4-yl)methanone (**24**)

Step c: To a solution of **23** (1.0 g, 5.2 mmol) in dry THF (5 mL) cooled at 0 °C, a 1 M solution of 4-chlorophenylmagnesium bromide (5.7 mL, 5.7 mmol) in Et₂O was added. Reaction was stirred at 25 °C for 6 h. The reaction was quenched with a saturated solution of NH₄Cl, THF was evaporated and residue was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by chromatography on silica gel (33% of EtOAc in PetEt) obtaining (4-chlorophenyl)(7-chloroquinolin-4-yl)methanol (1.3 g, 82%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ 8.84 (d, *J* = 4.3 Hz, 1H), 8.04 (s, 1H), 7.82 (d, *J* = 9.0 Hz, 1H), 7.63 (d, *J* = 4.4 Hz, 1H), 7.39 (d, *J* = 9.0 Hz, 1H), 7.33–7.21 (m, 4H), 6.40 (s, 1H); MS (ESI) *m/z* 304 [M+H]⁺.

Step d: To a solution of the above obtained compound (1.3 g, 4.3 mmol) in CHCl₃ (100 mL) MnO₂ (1.5 g, 17.1 mmol) was added. Suspension was stirred for 3 h at 25 °C and reaction was filtered through paper and solvent evaporated. Crude was purified by flash chromatography on silica gel (20% of EtOAc in PetEt) obtaining **24** (1.2 g, 92%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ 9.03 (d, *J* = 4.3 Hz, 1H), 8.21 (d, *J* = 2.1 Hz, 1H), 7.82 (s, 1H), 7.81–7.72 (m, 2H), 7.52 (d, *J* = 2.2 Hz, 1H), 7.51–7.43 (m, 2H), 7.38 (d, *J* = 4.3 Hz, 1H). MS (ESI) *m/z* 302 [M+H]⁺.

5.2.23. (4-(1,3-Dioxolan-2-yl)phenyl)(4-chlorophenyl)(7-chloroquinolin-4-yl)methanol (**25**)

To a solution of 2-(4-bromophenyl)-1,3-dioxolane (0.186 g, 0.8 mmol) in dry THF (10 mL) cooled at –70 °C a solution of *n*-BuLi (485 μL, 1.0 mmol) was added. Mixture was stirred at –70 °C for 30 min, then a solution of **24** (0.27 g, 0.9 mmol) in dry THF (5 mL) was added, and reaction was stirred for another 1.5 h at –70 °C. Thereafter, the reaction was allowed to reach 25 °C, water was added and THF was evaporated. Residue was extracted with EtOAc and the combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by chromatography on silica gel (20% of EtOAc in PetEt) obtaining **25** (0.287 g, 78%) as amorphous white solid. ¹H NMR (300 MHz, CDCl₃) δ 8.57 (d, *J* = 4.5 Hz, 1H), 8.11–7.84 (m, 2H), 7.44 (d, *J* = 8.0 Hz, 2H), 7.37–7.02 (m, 7H), 6.73 (d, *J* = 4.5 Hz, 1H), 5.77 (s, 1H), 4.31–3.79 (m, 5H); MS (ESI) *m/z* 452 [M+H]⁺.

5.2.24. *tert*-Butyl 4-(4-((4-chlorophenyl)(7-chloroquinolin-4-yl)(hydroxy)methyl)benzyl)piperazine-1-carboxylate (**26**)

Step f: Compound **25** (0.05 g, 0.1 mmol) was dissolved in water (2 mL) and the minimum amount of acetone necessary to have a limpid solution was added. Mixture was submitted under MW irradiation at 140 W, 100 °C for 30 min. Mixture was extracted with EtOAc and the combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. Residue 4-((4-chlorophenyl)(7-chloroquinolin-4-yl)(hydroxy)methyl)benzaldehyde (quantitative yield) was used in the next reaction without any further purification. ¹H NMR (300 MHz, CDCl₃) δ 10.02 (s, 1H), 8.72 (d, *J* = 4.6 Hz, 1H), 8.08 (s, 1H), 7.95 (d, *J* = 9.2 Hz, 1H), 7.87 (d, *J* = 8.0 Hz, 2H), 7.45 (d, *J* = 8.0 Hz, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.33–7.23 (m, 1H), 7.19 (d, *J* = 8.4 Hz, 2H), 6.76 (d, *J* = 4.4 Hz, 1H); MS (ESI) *m/z* 408 [M+H]⁺.

Step g: The above obtained compound (0.05 g, 0.12 mmol) was dissolved in a 1% solution of AcOH in EtOH (5 mL) and 1-Boc-piperazine (0.022 g, 0.1 mmol) and NaBH₃CN (0.015 g, 0.3 mmol) were added. Reaction was stirred at 25 °C for 12 h, then a saturated solution of NaHCO₃ was added, and EtOH was evaporated. Residue was extracted with DCM and the combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by chromatography on silica gel (1% of MeOH in DCM) obtaining **26** (0.06 g, 87%) as amorphous white solid. ¹H NMR (300 MHz, CDCl₃) δ 8.59 (d, *J* = 4.6 Hz, 1H), 8.05 (d, *J* = 9.3 Hz, 1H),

7.98 (d, *J* = 2.1 Hz, 1H), 7.39–7.08 (m, 9H), 6.75 (d, *J* = 4.6 Hz, 1H), 4.44 (br, 1H), 3.49 (s, 2H), 3.39 (br, 4H), 2.36 (br, 4H), 1.42 (s, 9H); MS (ESI) *m/z* 600 [M+Na]⁺.

5.2.25. 7-Chloro-4-((4-chlorophenyl)(4-(piperazin-1-ylmethyl)phenyl)methyl)quinoline (**5g**)

Compound **26** (0.025 g, 0.04 mmol) was dissolved in AcOH (5 mL) then a solution of H₃PO₄ (123 μL, 0.19 mmol) 50% in water and a catalytic amount of iodine were added. Reaction was stirred at 60 °C for 12 h and water was added. AcOH was evaporated under reduced pressure; residue was neutralized with NaHCO₃ and extracted with DCM. The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by chromatography on alumina (5% of MeOH in DCM) obtaining **28** (0.015 g, 80%) as amorphous white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.78 (d, *J* = 4.5 Hz, 1H), 8.10 (d, *J* = 1.9 Hz, 1H), 7.81 (d, *J* = 9.0 Hz, 1H), 7.37 (dd, *J* = 9.0, 2.0 Hz, 1H), 7.33–7.19 (m, 5H), 6.98 (dd, *J* = 8.1, 3.7 Hz, 3H), 6.81 (d, *J* = 4.5 Hz, 1H), 6.10 (s, 1H), 3.45 (s, 2H), 2.86 (br, 4H), 2.39 (br, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 151.3, 149.1, 149.0, 140.4, 140.2, 136.3, 135.0, 133.0, 130.7, 129.5, 129.4, 129.2, 129.0, 127.8, 125.5, 122.1, 62.3, 52.9, 51.8, 50.9, 44.2; HRMS-ESI *m/z*: calcd for C₂₇H₂₆Cl₂N₃⁺ [M+H]⁺: 462.1498; found: 462.1504; MS (ESI) *m/z* 462 [M+H]⁺. HPLC RT: 10.2 min.

5.2.26. (4-Chlorophenyl)(7-chloroquinolin-4-yl)(4-(piperazin-1-ylmethyl)phenyl)methanol (**5h**)

To a solution of **26** (0.035 g, 0.06) in dry DCM (3 mL) TFA (250 μL) was added and mixture was stirred at 1.5 h at 25 °C. Reaction was quenched with NaHCO₃ and extracted with DCM. The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. The crude material was purified by chromatography on alumina (2% of MeOH in DCM) obtaining **5h** (0.02 g, 68%) as amorphous white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, *J* = 4.6 Hz, 1H), 8.15–7.88 (m, 2H), 7.42–7.03 (m, 9H), 6.77 (d, *J* = 4.6 Hz, 1H), 3.43 (s, 2H), 2.73 (br, 4H), 2.33 (br, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 151.0, 150.5, 150.0, 144.1, 143.8, 137.3, 134.8, 133.8, 129.5, 129.1, 128.9, 128.5, 127.5, 127.1, 124.7, 121.8, 82.1, 62.5, 52.0 (2C), 44.7; HRMS-ESI *m/z*: calcd for C₂₇H₂₆Cl₂N₃O⁺ [M+H]⁺: 478.1447; found: 478.1455; MS (ESI) *m/z* 478 [M+H]⁺. HPLC RT 9.6 min.

5.2.27. 3-Methyl-1H-1,2,4-triazol-5-amine (**28**)

To aminoguanidine bicarbonate (2.0 g, 14.7 mmol) AcOH (2 mL) was added. Mixture was stirred at 25 °C until effervescence had completely vanished, then toluene (100 mL) was added, reaction was linked to a dean-stark system and heated at 110 °C for 12 h. Solvent was evaporated and residue was purified by chromatography on silica gel (1% MeOH, 1.1% NH₄OH in DCM). **28** (1.2, 86%) was obtained as a white solid. ¹H NMR: (300 MHz, DMSO) δ 5.47 (br, 2H), 2.03 (s, 3H), 1.85 (s, 1H); ESI MS *m/z*: 99 [M + H]⁺; m.p. 143–145 °C.

5.2.28. 5,7-Dichloro-2-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidine (**29**)

To 20 mL of dry EtOH Na⁰ (0.32 g, 13.9 mmol) was added at 0 °C; after complete Na solubilization compound **28** (1.1 g, 11.6 mmol) and diethyl malonate (2 mL, 13.2 mmol) were added. The reaction was heated at 80 °C for 12 h. A white precipitate was obtained and collected, then it was washed with EtOH, solubilized in water, and precipitated again with HCl 37%. The white solid obtained was collected, obtaining 2-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidine-5,7-diol (1.2 g, 62%). ¹H NMR: (300 MHz, DMSO) δ 12.24 (br, 2H), 5.04 (s, 1H), 2.33 (s, 3H); ESI MS *m/z*: 167 [M + H]⁺; m.p. decomposition at 220 °C.

The above obtained compound ((1.2 g, 7.22 mmol) was suspended in POCl₃ (20 mL) and stirred at 110 °C for 12 h POCl₃ was evaporated and the residue was neutralized with a saturated

solution of NaHCO₃, and extracted with DCM. The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. Crude compound was purified by chromatography on silica gel (2% MeOH in DCM) obtaining **29** (0.883 g, 60%) as a white solid. ¹H NMR: (300 MHz, CDCl₃) δ 7.17 (s, 1H), 2.67 (s, 3H); MS (ESI) *m/z*: 202 [M + H]⁺; m.p. 222–224 °C.

5.2.29. *tert*-Butyl 4-(4-(amino(3-chlorophenyl)methyl)benzyl)piperazine-1-carboxylate (**30**)

Step g: To a solution of **32** (0.44 g, 1.1 mmol) in EtOH (20 mL) BaCO₃ (0.481 g, 2.4 mmol) and NH₂OH·HCl (0.157 g, 2.4 mmol) were added. Reaction was stirred at 65 °C for 12 h, then was filtered through celite and solvent was evaporated. (*E,Z*)-*tert*-Butyl 4-(4-((3-chlorophenyl)(hydroxyimino)-methyl)benzyl)piperazine-1-carboxylate (0.46 g, quantitative yield) was obtained as an amorphous white solid and was used in the next step without any further purification. ¹H NMR: (400 MHz, CDCl₃) δ 8.34 (br, 1H), 7.51–7.19 (m, 8H), 3.52 (br, 6H), 2.31 (br, 4H), 1.43 (s, 9H); MS (ESI) *m/z*: 430 [M + H]⁺.

Step h: To a solution of the above-obtained compound (0.46 g, 1.1 mmol) in AcOH (50 mL) NH₄Cl (1.2 g, 22.3 mmol) and Zn⁰ (2.7 g, 41.9 mmol) were added. Reaction was stirred at 50 °C for 12 h then was filtered through celite, solvent was evaporated, and residue neutralized with NaHCO₃. Mixture was extracted with DCM, and the combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. Crude **30** (0.30 g, 70%) obtained as a pale-yellow oil, was used in the next step without any further purification. ¹H NMR: (400 MHz, CDCl₃) δ 7.36 (s, 1H), 7.30–7.12 (m, 7H), 5.12 (s, 1H), 3.43 (s, 2H), 3.38 (br, 4H), 2.33 (br, 4H), 1.83 (br, 2H), 1.42 (s, 9H); MS (ESI) *m/z*: 416 [M + H]⁺.

5.2.30. *tert*-Butyl 4-(4-(((5-chloro-2-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-7-yl)amino)(3-chlorophenyl)methyl)benzyl)piperazine-1-carboxylate (**31**)

Compound **29** (0.07 g, 0.4 mmol) and **30** (0.216 g, 0.5 mmol) were dissolved in EtOH (5 mL) and the reaction was stirred at 25 °C for 12 h. The solvent was evaporated, and the crude was purified by chromatography on silica gel (3% MeOH in DCM) obtaining **31** (0.20 g, 66%). ¹H NMR: (400 MHz, CDCl₃) δ 7.44–7.17 (m, 8H), 6.59 (d, *J* = 5.9 Hz, 1H), 5.90 (s, 1H), 5.72 (d, *J* = 6.0 Hz, 1H), 3.48 (s, 2H), 3.42 (br, 4H), 2.52 (s, 3H), 2.37 (br, 4H), 1.43 (s, 9H); MS (ESI) *m/z*: 582 [M + H]⁺.

5.2.31. *N*-((3-Chlorophenyl)(4-(piperazin-1-ylmethyl)phenyl)methyl)-5-methoxy-2-methyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-7-amine (**5k**)

To dry MeOH (2 mL) placed in a microwave tube, and cooled at 0 °C, metallic sodium (0.015 g, 0.70 mmol) was added. After complete dissolution of sodium, compound **31** (0.06 g, 0.10 mmol) was added and the mixture was heated to 85 °C under microwave irradiation 80 W for 30 min. Water was slowly added and the mixture was extracted with DCM; the combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. Crude **5k** was purified by chromatography on alumina (MeOH 5% in DCM) and was obtained as a colorless oil (0.025 g, 54%). ¹H NMR: (400 MHz, CDCl₃) δ 7.48–7.10 (m, 8H), 6.32 (s, 1H), 5.62 (s, 1H), 5.28 (s, 1H), 3.91 (s, 3H), 3.45 (s, 2H), 2.86 (br, 4H), 2.47 (s, 3H), 2.35 (br, 4H); ¹³C NMR: (75 MHz, CDCl₃) δ 167.4, 164.2, 155.5, 146.8, 141.8, 139.2, 138.0, 135.4, 130.7, 130.2 (2C), 128.8, 127.5 (2C), 125.4, 63.2, 60.9, 54.4, 46.1, 15.1; MS (ESI) *m/z*: 500 [M + Na]⁺; HRMS-ESI *m/z*: calcd for C₂₅H₂₉ClN₇O⁺ [M+H]⁺: 478.2117; found: 478.2121; HPLC RT: 9.2 min.

5.2.32. *tert*-Butyl 4-(4-(3-hydroxybenzoyl)benzyl)piperazine-1-carboxylate (**33**)

Step a: **14** (1.0 g, 1.6 mmol) was dissolved in DCE (50 mL) and 85% MnO₂ (0.655 g, 6.40 mmol) was added. The reaction was stirred at 80 °C for 6 h then it was filtered through paper and the solvent was evaporated. *tert*-Butyl 4-(4-(3-((*tert*-butyldiphenylsilyl)-oxy)-benzoyl)benzyl)piperazine-1-carboxylate (0.725 g, 70%) was obtained as a pale yellow oil and it was used in the next step without further purifications. ¹H NMR: (300 MHz, CDCl₃) δ 7.75–7.63 (m, 3H), 7.58 (d, *J* = 8.0 Hz, 2H), 7.47–7.24 (m, 10H), 7.22–7.12 (m, 2H), 6.99–6.91 (m, 1H), 3.55 (s, 2H), 3.45 (br, 4H), 2.40 (br, 4H), 1.46 (s, 9H), 1.10 (s, 9H); MS (ESI) *m/z*: 635 [M + H]⁺.

Step b: Compound **33** was obtained from the above compound (0.084 g, 0.1 mmol) following the procedure described before for compound **5f** step g. Crude was purified by chromatography on silica gel (3% MeOH, in DCM) obtaining **33** (0.05 g, 97%) as a white solid. ¹H NMR: (300 MHz, CDCl₃) δ 7.70 (d, *J* = 8.0 Hz, 2H), 7.37 (d, *J* = 8.1 Hz, 2H), 7.30–7.19 (m, 3H), 7.05 (d, *J* = 7.7 Hz, 1H), 3.54 (s, 2H), 3.42 (br, 4H), 2.40 (br, 4H), 1.43 (s, 9H); MS (ESI) *m/z*: [M + H]⁺ 397; m.p. 157–159 °C.

5.2.33. *tert*-Butyl 4-(4-(3-(2-((methylsulfonyl)oxy)ethoxy)benzoyl)benzyl)piperazine-1-carboxylate (**34**)

To a solution of **33** (0.10 g, 0.3 mmol) in dry DMF (5 mL) NaH (0.012 g, 0.5 mmol) was added. The reaction was heated at 80 °C and a solution of ethylene glycol dimesylate (0.065 g, 0.3 mmol) in dry DMF (2 mL) was added. The mixture was stirred at 80 °C for 2 h, then DMF was evaporated and crude was treated with water. The residue was extracted with DCM and the combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. Crude compound was purified by chromatography on silica gel (2% MeOH in DCM). **34** (0.041 g, 27%) was obtained as a pale-yellow oil. ¹H NMR: (400 MHz, CDCl₃) δ 7.74 (d, *J* = 8.1 Hz, 2H), 7.43 (d, *J* = 8.0 Hz, 2H), 7.36 (t, *J* = 9.6 Hz, 3H), 7.12 (d, *J* = 7.2 Hz, 1H), 4.57 (t, *J* = 4.0 Hz, 2H), 4.29 (t, *J* = 4.0 Hz, 2H), 3.56 (s, 2H), 3.42 (br, 4H), 3.05 (s, 3H), 2.39 (br, 4H), 1.44 (s, 9H); MS (ESI) *m/z*: 519 [M + H]⁺.

5.2.34. *Di-tert*-butyl 4,4'-((((ethane-1,2-diylbis(oxy))bis(3,1-phenylene))bis(hydroxymethylene))-bis(4,1-phenylene))bis(methylene))bis(piperazine-1-carboxylate (**35**)

Step d: To a solution of **33** (0.031 g, 0.1 mmol) in dry DMF (2 mL) NaH (0.003 g, 0.1 mmol) was added. The mixture was stirred at 80 °C and **34** (0.034 g, 0.1 mmol) was added; the reaction was stirred at 80 °C for 2 h. Then DMF was evaporated, water was added to the residue and mixture was extracted with DCM. The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. Crude compound was purified by chromatography on silica gel (2% MeOH in DCM) obtaining *di-tert*-butyl 4,4'-(((3,3'-(ethane-1,2-diylbis(oxy))bis(benzoyl))bis(4,1-phenylene))bis(methylene))bis(piperazine-1-carboxylate (0.038 g, 71%) as a pale yellow oil. ¹H NMR: (300 MHz, CDCl₃) δ 7.76 (d, *J* = 7.9 Hz, 4H), 7.50–7.31 (m, 9H), 7.23–7.09 (m, 3H), 4.39 (s, 4H), 3.58 (s, 4H), 3.44 (br, 8H), 2.41 (br, 8H), 1.45 (s, 18H); MS (ESI) *m/z*: 819 [M + H]⁺.

Step e: The above obtained compound (0.098 g, 0.13 mmol) was dissolved in THF (5 mL), cooled at 0 °C, then NaBH₄ (0.012 g, 0.33 mmol) was added. The reaction was stirred at 25 °C for 12 h then water was added, and the mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. **35** (0.10 g, quantitative yield) was obtained as a colorless oil and used in the next step without any further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.13 (m, 10H), 7.02–6.87 (m, 4H), 6.79 (dd, *J* = 8.3, 2.6 Hz, 2H), 5.74 (s, 2H), 4.24 (s, 4H), 3.43 (s, 4H), 3.35 (t, *J* = 5.0 Hz, 8H), 2.82 (s, 2H), 2.31 (t, *J* = 5.0 Hz, 8H), 1.42 (s, 18H); MS (ESI) *m/z*: 823 [M + H]⁺.

5.2.35. *N,N'*-(((Ethane-1,2-diybis(oxy)))bis(3,1-phenylene))bis((4-(piperazin-1-ylmethyl)phenyl)-methylene))bis(7-chloroquinolin-4-amine) (**5m**)

Step f: Compound *di-tert-butyl 4,4'*-((((ethane-1,2-diybis(oxy)))bis(3,1-phenylene))-bis(chloro-methylene))bis(4,1-phenylene))bis(-methylene))bis(piperazine-1-carboxylate) (0.103 g, quantitative yield) was obtained as a brown oil, starting from **35** and following the procedure used before to obtain compound **6a**. It was used in the next step without any further purification. ¹H NMR: (300 MHz, CDCl₃) δ 7.41–7.18 (m, 10H), 7.09–6.96 (m, 4H), 6.86 (dd, *J* = 7.9, 2.1 Hz, 2H), 6.07 (s, 2H), 4.29 (s, 4H), 3.47 (s, 4H), 3.41 (br, 8H), 2.37 (br, 8H), 1.46 (s, 18H); MS (ESI) *m/z*: 859 [M + H]⁺.

Step g: Compound *di-tert-butyl 4,4'*-((((ethane-1,2-diybis(oxy)))bis(3,1-phenylene))bis(((7-chloroquinolin-4-yl)amino)methylene))bis(4,1-phenylene))bis(methylene))bis(piperazine-1-carboxylate) was obtained starting from the above-obtained compound (0.075 g, 0.1 mmol) following the procedure used for compound **5a**. Crude was purified by chromatography obtaining the desired compound as a pale yellow oil (0.017 g, 17%). ¹H NMR: (300 MHz, CDCl₃) δ 8.48–8.38 (m, 2H), 7.97 (s, 2H), 7.72 (d, *J* = 9.1 Hz, 2H), 7.40–7.24 (m, 12H), 7.04–6.90 (m, 4H), 6.84 (d, *J* = 8.1 Hz, 2H), 6.25 (d, *J* = 5.4 Hz, 2H), 5.67 (s, 2H), 5.49 (s, 2H), 4.23 (s, 4H), 3.49 (s, 4H), 3.42 (br, 8H), 2.38 (br, 8H), 1.45 (s, 18H); MS (ESI) *m/z*: 572 [M + 2H]²⁺.

Step h: Compound **5m** was obtained starting from the above-obtained compound (0.017 g, 0.02 mmol) following the same procedure used to obtain **5e**. Crude was purified by HPLC equipped with a UV-VIS detector (Diode Array SPD-M20A) and the column used was Chromolith® Semiprep RP-18e (100–10 mm). All runs were performed in gradient mode (flow rate = 2.5 mL/min; gradient, 80/20–5/95 A/B in 10 min; isocratic 5/95 A/B 5 min) at 25 °C with detection at 254 nM. Sample solutions were prepared (approximately 2 mg/mL) by dissolving the analytes in the eluent and filtering through 0.45 μm Acrodisc filters. The injection volume was 50 μL and RT of **5e** was 5.94 min **5e** (0.006 g, 50%) was obtained as a pale-yellow oil.

¹H NMR: (300 MHz, CDCl₃) δ 8.41 (d, *J* = 3.1 Hz, 2H), 8.09 (d, *J* = 5.1 Hz, 1H), 7.96 (d, *J* = 1.8 Hz, 1H), 7.71 (d, *J* = 9.0 Hz, 2H), 7.43–7.22 (m, 14H), 7.04–6.71 (m, 6H), 6.25 (d, *J* = 5.3 Hz, 2H), 5.66 (s, 2H), 5.45 (s, 2H), 4.23 (s, 4H), 3.47 (s, 4H), 2.87 (br, 8H), 2.41 (br, 8H); MS (ESI) *m/z*: 472 [M + 2H]²⁺.

5.3. Expression of PfCRT in *Xenopus* oocytes and measurements of CQ transport

Ethical approval of the work performed with the *Xenopus laevis* frogs was obtained from the Australian National University Animal Experimentation Ethics Committee (Animal Ethics Protocol Number A2013/13) in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Sections of ovary were surgically removed from adult female frogs (purchased from NASCO) using a procedure outlined in detail elsewhere [46]. Single oocytes were obtained by incubating the ovary sections with collagenase in accordance with a protocol described previously [46] and with the following minor modification: the ovary tissue (weighing 7–14 g) was transferred to a 100 mL Erlenmeyer flask and incubated in the dark in OR²⁻ buffer supplemented with 0.5 M Na₂HPO₄ (Sigma-Aldrich), bovine serum albumin (250 mg/mL, Sigma-Aldrich), 5–10 μg/mL of collagenase (of which 60% was collagenase A and 40% collagenase D; Roche), and 40–100 μg/mL of soybean trypsin inhibitor (type II-S; Sigma-Aldrich). Healthy, defolliculated oocytes of a suitable size and age (developmental stages V and VI) were selected for microinjection. cRNA encoding PfCRT^{Dd2} was transcribed *in vitro* and microinjected (20 ng per oocyte) into the oocytes as outlined elsewhere [28,46]. The oocytes

were stored in the dark at 16–18 °C in OR²⁺ buffer (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl₂, 1 mM Na₂HPO₄, 5 mM HEPES, 1 mM CaCl₂, and 50 μg/mL gentamicin; pH 7.8), which was replaced daily. The uptake of [³H]CQ (0.25 μM; 20 Ci/mmol; American Radio-labeled Chemicals) was measured 3–4 days post-injection using a MicroBeta² microplate liquid scintillation analyzer (PerkinElmer) and a protocol described in detail previously [28]. Briefly, the [³H] CQ influx assays were performed over 1.5 h at 27.5 °C and in a medium that contained 96 mM NaCl, 2 mM KCl, 2 mM MgCl₂, 1.8 mM CaCl₂, 10 mM MES, 10 mM Tris base (pH 5.5), and 15 μM unlabeled CQ. In all cases, at least three independent experiments were performed (on oocytes from different frogs), and in each experiment measurements were made from 10 oocytes per treatment. All errors cited in the text and shown in the figures represent the s.e.m. Statistical comparisons were made using one-way ANOVAs in conjunction with Tukey's multiple comparisons test.

5.4. Transmission blocking assay

5.4.1. Murine malaria model

Plasmodium berghei ANKA GFP-con strain, expressing a green fluorescent protein (GFP) at all life cycle stages was employed in the *in vivo* Direct Feeding Assay (DFA). BALB/c mice were used as vertebrate hosts and *An. stephensi* mosquitoes as experimental vectors.

5.4.2. Mice

Eight to ten-week-old BALB/c mice, weighing 18–25 g were used in this study. The mice were reared in the animal house (24 °C, 14 h light/10 h dark cycle and 70% relative humidity) of the University of Camerino and were fed *ad-libitum* with standard mouse food (Mucedola s.r.l., Milano, Italy) and tap water.

5.4.3. Mosquitoes

Anopheles stephensi mosquitoes were maintained at a temperature of 30 °C, 12 h light/12 h dark cycle and 75–85% relative humidity in the insectary of the University of Camerino. Larvae were raised in the same facility in trays filled with well water and fed with grinded mouse food. Four to five-day old female mosquitoes were used in the experimentations. Mosquito cages were transferred to a 19 °C chamber 24 h prior to the experimental blood-meals to allow sporogonic development to be completed which in the case of *P. berghei* requires a temperature between 18 and 20 °C.

5.5. Direct Feeding Assay (DFA)

The transmission blocking activity of the compounds was evaluated in a double *in vivo* assay including both, the mouse, and the mosquito host. The effects of the compounds on gametocytes in the mouse and on early sporogonic development to oocyst formation in mosquitoes was tested as described in detail before [47].

Experimental mice received a standardized i.p. infection with 10⁷ *P. berghei* GFP-con infected red blood cells. In the morning of day 3 after mouse infection parasitemia and gametocytemia was determined on Giemsa stained thin films. Mice showing a parasitemia of about 5% (3–10%) with the presence of micro- and macrogametocytes were selected for the DFA and allocated randomly to the four treatment groups (3 mice per group), namely PQ derivative **5i** and **5j**, PBS solvent control and PQ as positive reference. In the afternoon of day 3 post infection, i.e. at the time point of *P. berghei* gametocyte maturation, a first treatment was carried out by administering (i.p.) compounds **5i**, **5j** and PQ at a dosage of 10 μmol/kg to the treatment mice and giving plain PBS to controls. On day four post-infection, the treatment was repeated

1.5 h before the exposure of mice to mosquitoes. Experimental animals were anaesthetized and kept on top of cages containing approximately 150 female *A. stephensi* mosquitoes for 1 h. Unfed females were removed the following day. On day 8 after blood-meal, 20–30 mosquitoes (minimum 8) from each cage were dissected and oocyst densities assessed by counting the number of fluorescent oocysts on mosquito mid-guts at the fluorescent microscope (Zeiss Axio observer Z1, 60–100 x magnification) (Fig. S2). Experimental treatments were affected in triplicates, using for each treatment or control group 3 mice for the infection of 3 mosquito cages. For each mosquito cage, the geometric mean number of oocysts and the standard deviation was assessed on positive mosquitoes and the arithmetic mean calculated for each treatment using the geometric means of the 3 replicates. Differences in mean oocyst numbers between each of the 2 PQ derivative treatment groups and the solvent control were evaluated by *t*-test (two-tailed).

5.6. Liver-stage analysis

6–12 weeks of age BALB/cJrj (Janvier-laboratories) mice were infected by i.p. injection of PbmCherry_{hsp70} blood stabilities [48]. At around 2% parasitemia (~day 3) blood was passaged i.v. into naïve mice. When these mice reached parasitemia of about 5% (around day 3) thin blood smears were stained using Wright stain and gametocyte development was examined. Mice necessary to infect mosquitoes were anesthetized with a mixture of 50 mg/kg Ketamine and 10 mg/kg.

Xylazine in PBS by i.p., route. After reaching deep anesthesia they were placed on a mosquito cage for 30 min where mosquitoes (female *Anopheles stephensi*) could take a blood meal. Mosquitoes were kept at 20.5 °C and 80% humidity (12 h/12 h light-dark cycle). Between 18- and 26-days post feed, salivary glands of *Plasmodium berghei* infected mosquitoes were dissected and used to infect HepG2 cells.

Confluent HepG2 cell cultures (60000 cells/96 well seeded the day before) were infected with 20'000 *P. berghei* sporozoites each (PbmCherry_{hsp70}) for 2 h. In total 6 replicates with 3 wells each were infected. The cells of each replicate were detached by the use of accutase (Innovative Cell Technologies) pooled and distributed to 3 times 8 wells containing either primaquine, **5i** or **5j**, each at different concentrations plus control (DMSO same concentration as in highest drug concentration). Media were changed at 24 hpi, and the cells were fixed with 4% PFA/PBS at 48 hpi. Host cell growth was monitored by phase contrast microscopy to evaluate growth inhibiting drug concentrations. Parasite numbers and sizes were determined by automated microscopy (IN Cell analyzer, GE life sciences) monitoring the mCherry signal of PbmCherry_{hsp70} parasites [49]. Statistical evaluations (One-way ANOVA with Dunnett's multiple comparisons) were done using Prism 8 (GraphPad).

5.7. Cytotoxicity assay on NIH3T3 cell line

Cells (5×10^4) suspended in 1 mL of complete medium were seeded in each well of a 24 well round multidish and incubated at 37 °C in an atmosphere of 5% CO₂. After 24 h of culture, the culture medium was discharged and test samples, solubilized in DMSO, were added to each well at different concentration values. For the evaluation of cytotoxicity, three experiments repeated in six replicates were performed and all compounds were tested at increasing concentrations ranging from 8 to 160 μM. The samples were set up in six replicates for each tested concentration. Complete medium was used as negative control. Cell viability and proliferation was evaluated by Neutral Red uptake after 24 h of incubation with NIH3T3 as follows.

First, the following solutions were prepared in order to determine the percentage of viable cells:

1. Neutral Red (NR) stock solution: 0.33 g NR dye powder in 100 ml sterile H₂O
2. NR medium: 1.0 mL NR stock solution +99.0 routine culture medium pre-warmed to 37 °C
3. NR desorb solution: 1% glacial acetic acid solution +50% ethanol +49% H₂O

At the end of incubation, the routine culture medium was removed from each plate and the cells were carefully rinsed with 1 ml pre-warmed D-PBS 0.1 M. Plates were then gently blotted with paper towels. 1.0 ml NR medium was added to each dish and further incubated at 37 °C, 95% humidity, 5.0% CO₂ for 3 h. The cells were checked during incubation for NR crystal formation. After incubation, the NR medium was removed, and the cells were carefully rinsed with 1 mL pre-warmed D-PBS 0.1 M. PBS was decanted and blotted from the dishes and exactly 1 mL NR desorb solution was added to each sample. Plates were placed on a shaker for 20–45 min to extract NR from the cells and form a homogeneous solution. During this step the samples were covered to protect them from light. Five minutes after removal from the shaker, absorbance was read at 540 nm with a UV/visible spectrophotometer (Varian Cary 1 E).

Author contributions

The manuscript was written through contribution of all authors. All authors have given approval to the final version of the manuscript.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

Authors thank MIUR Progetto Dipartimento di Eccellenza DBCF-UNISI 2018–2022. Financial contribution from MIUR is kindly acknowledged (Project PRIN 20154JRJPP).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejmech.2021.113227>.

References

- [1] World Health Organization, World Malaria Report 2019, Geneva, 2019.
- [2] O. Müller, G.Y. Lu, L. von Seidlein, Geographic expansion of artemisinin resistance, *J. Trav. Med.* 26 (2019), <https://doi.org/10.1093/jtm/taz030>.
- [3] J.-F. Trape, G. Pison, A. Spiegel, C. Enel, C. Rogier, Combating malaria in africa, *Trends Parasitol.* 18 (2002) 224–230, [https://doi.org/10.1016/S1471-4922\(02\)02249-3](https://doi.org/10.1016/S1471-4922(02)02249-3).
- [4] S. Pulcini, H.M. Staines, A.H. Lee, S.H. Shafik, G. Bouyer, C.M. Moore, D.A. Daley, M.J. Hoke, L.M. Altenhofen, H.J. Painter, J. Mu, D.J.P. Ferguson, M. Llinás, R.E. Martin, D.A. Fidock, R.A. Cooper, S. Krishna, Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite's food vacuole and alter drug sensitivities, *Sci. Rep.* 5 (2015) 14552, <https://doi.org/10.1038/srep14552>.
- [5] S.K. Martin, A.M. Oduola, W.K. Milhous, Reversal of chloroquine resistance in Plasmodium falciparum by verapamil, *Science* 235 (1987) 899–901, <https://doi.org/10.1126/science.3544220>, 80-.
- [6] R.E. Martin, S.H. Shafik, S.N. Richards, Mechanisms of resistance to the partner drugs of artemisinin in the malaria parasite, *Curr. Opin. Pharmacol.* 42 (2018) 71–80, <https://doi.org/10.1016/j.coph.2018.07.010>.

- [7] R.E. Martin, R. V Marchetti, A.I. Cowan, S.M. Howitt, S. Bröer, K. Kirk, Chloroquine transport via the malaria parasite's chloroquine resistance transporter, *Science* 325 (2009) 1680–1682, <https://doi.org/10.1126/science.1175667>, 80–.
- [8] R.L. Summers, A. Dave, T.J. Dolstra, S. Bellanca, R. V Marchetti, M.N. Nash, S.N. Richards, V. Goh, R.L. Schenk, W.D. Stein, K. Kirk, C.P. Sanchez, M. Lanzer, R.E. Martin, Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite's chloroquine resistance transporter, *Proc. Natl. Acad. Sci. Unit. States Am.* 111 (2014) E1759, <https://doi.org/10.1073/pnas.1322965111>. LP-E1767.
- [9] A.M. Lehane, R. Hayward, K.J. Saliba, K. Kirk, A verapamil-sensitive chloroquine-associated H⁺ leak from the digestive vacuole in chloroquine-resistant malaria parasites, *J. Cell Sci.* 121 (2008) 1624, <https://doi.org/10.1242/jcs.016758>. LP – 1632.
- [10] A.M. Lehane, K. Kirk, Chloroquine resistance-conferring mutations in pfCRT give rise to a chloroquine-associated H⁺ leak from the malaria parasite's digestive vacuole, *Antimicrob. Agents Chemother.* 52 (2008) 4374, <https://doi.org/10.1128/AAC.00666-08>. LP – 4380.
- [11] D.A. Fidock, T. Nomura, A.K. Talley, R.A. Cooper, S.M. Dzekunov, M.T. Ferdig, L.M.B. Ursos, A. bir Singh Sidhu, B. Naudé, K.W. Deitsch, X. Su, J.C. Wootton, P.D. Roepe, T.E. Wellems, Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance, *Mol. Cell.* 6 (2000) 861–871, [https://doi.org/10.1016/S1097-2765\(05\)00077-8](https://doi.org/10.1016/S1097-2765(05)00077-8).
- [12] D.A. Cooper, M.T. Ferdig, X.-Z. Su, L.M.B. Ursos, J. Mu, T. Nomura, H. Fujioka, D.A. Fidock, P.D. Roepe, T.E. Wellems, Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum, *Mol. Pharmacol.* 61 (2002) 35, <https://doi.org/10.1124/mol.61.1.35>. LP – 42.
- [13] P.G. Bray, S. Deed, E. Fox, M. Kalkanidis, M. Mungthin, L.W. Deady, L. Tilley, Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum, *Biochem. Pharmacol.* 70 (2005) 1158–1166, <https://doi.org/10.1016/j.bcp.2005.07.021>.
- [14] K.J. Deane, R.L. Summers, A.M. Lehane, R.E. Martin, R.A. Barrow, Chlorpheniramine analogues reverse chloroquine resistance in Plasmodium falciparum by inhibiting PfCRT, *ACS Med. Chem. Lett.* 5 (2014) 576–581, <https://doi.org/10.1021/ml5000228>.
- [15] P.G. Bray, S.A. Ward, A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in Plasmodium falciparum, *Pharmacol. Ther.* 77 (1998) 1–28, [https://doi.org/10.1016/S0163-7258\(97\)00083-1](https://doi.org/10.1016/S0163-7258(97)00083-1).
- [16] R.E. Martin, A.S. Butterworth, D.L. Gardiner, K. Kirk, J.S. McCarthy, T.S. Skinner-Adams, Saquinavir inhibits the malaria parasite's chloroquine resistance transporter, *Antimicrob. Agents Chemother.* 56 (2012) 2283–2289, <https://doi.org/10.1128/AAC.00166-12>.
- [17] S. Bellanca, R.L. Summers, M. Meyrath, A. Dave, M.N. Nash, M. Dittmer, C.P. Sanchez, W.D. Stein, R.E. Martin, M. Lanzer, Multiple drugs compete for transport via the Plasmodium falciparum chloroquine resistance transporter at distinct but interdependent sites, *J. Biol. Chem.* 289 (2014) 36336–36351, <https://doi.org/10.1074/jbc.M114.614206>.
- [18] A.M. Lehane, K. Kirk, Efflux of a range of antimalarial drugs and 'chloroquine resistance reversers' from the digestive vacuole in malaria parasites with mutant PfCRT, *Mol. Microbiol.* 77 (2010) 1039–1051, <https://doi.org/10.1111/j.1365-2958.2010.07272.x>.
- [19] D.A. van Schalkwyk, T.J. Egan, Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum, *Drug Resist. Updates* 9 (2006) 211–226, <https://doi.org/10.1016/j.drug.2006.09.002>.
- [20] R.E. Martin, The transportome of the malaria parasite, *Biol. Rev.* 95 (2020) 305–332, <https://doi.org/10.1111/bvr.12565>.
- [21] S.H. Shafik, S.A. Cobbold, K. Barkat, S.N. Richards, N.S. Lancaster, M. Llinás, S.J. Hogg, R.L. Summers, M.J. McConville, R.E. Martin, The natural function of the malaria parasite's chloroquine resistance transporter, *Nat. Commun.* 11 (2020) 3922, <https://doi.org/10.1038/s41467-020-17781-6>.
- [22] S. D'Alessandro, G. Alfano, L. Di Cerbo, S. Brogi, G. Chemi, N. Relitti, M. Brindisi, S. Lamponi, E. Novellino, G. Campiani, S. Gemma, N. Basilio, D. Taramelli, M.C. Baratto, R. Pogni, S. Butini, Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II), *Bioorg. Chem.* 89 (2019) 103020, <https://doi.org/10.1016/j.bioorg.2019.103020>.
- [23] A. Vallone, S. D'Alessandro, S. Brogi, M. Brindisi, G. Chemi, G. Alfano, S. Lamponi, S.G. Lee, J.M. Jez, K.J.M. Koolen, K.J. Decherling, S. Saponara, F. Fusi, B. Gorelli, D. Taramelli, S. Parapini, R. Caldelari, G. Campiani, S. Gemma, S. Butini, Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analog, *Eur. J. Med. Chem.* 150 (2018) 698–718, <https://doi.org/10.1016/j.ejmech.2018.03.024>.
- [24] S. Gemma, C. Camodeca, S. Sanna Coccone, B.P. Joshi, M. Bernetti, V. Moretti, S. Brogi, M.C. Bonache de Marcos, L. Savini, D. Taramelli, N. Basilio, S. Parapini, M. Rottmann, R. Brun, S. Lamponi, S. Caccia, G. Guiso, R.L. Summers, R.E. Martin, S. Saponara, B. Gorelli, E. Novellino, G. Campiani, S. Butini, Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling, *J. Med. Chem.* 55 (2012) 6948–6967, <https://doi.org/10.1021/jm300802s>.
- [25] S. Gemma, G. Campiani, S. Butini, G. Kukreja, S.S. Coccone, B.P. Joshi, M. Persico, V. Nacci, I. Fiorini, E. Novellino, E. Fattorusso, O. Tagliatela-Scafati, L. Savini, D. Taramelli, N. Basilio, S. Parapini, G. Morace, V. Yardley, S. Croft, M. Coletta, S. Marini, C. Fattorusso, Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies, *J. Med. Chem.* 51 (2008) 1278–1294, <https://doi.org/10.1021/jm701247k>.
- [26] S. Gemma, G. Campiani, S. Butini, G. Kukreja, B.P. Joshi, M. Persico, B. Catalanotti, E. Novellino, E. Fattorusso, V. Nacci, L. Savini, D. Taramelli, N. Basilio, G. Morace, V. Yardley, C. Fattorusso, Design and synthesis of potent antimalarial agents based on clotrimazole Scaffold: exploring an innovative pharmacophore, *J. Med. Chem.* 50 (2007) 595–598, <https://doi.org/10.1021/jm061429p>.
- [27] J.L. Small-Saunders, L.M. Hagenah, D.A. Fidock, Turning the tide: targeting PfCRT to combat drug-resistant P. falciparum? *Nat. Rev. Microbiol.* 18 (2020) 261–262, <https://doi.org/10.1038/s41579-020-0353-8>.
- [28] S.N. Richards, M.N. Nash, E.S. Baker, M.W. Webster, A.M. Lehane, S.H. Shafik, R.E. Martin, Molecular mechanisms for drug hypersensitivity induced by the malaria parasite's chloroquine resistance transporter, *PLoS Pathog.* 12 (2016), e1005725, <https://doi.org/10.1371/journal.ppat.1005725>.
- [29] C.A. Hrycyna, R.L. Summers, A.M. Lehane, M.M. Pires, H. Namanja, K. Bohn, J. Kuriakose, M. Ferdig, P.P. Henrich, D.A. Fidock, K. Kirk, J. Chmielewski, R.E. Martin, Quinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparum, *ACS Chem. Biol.* 9 (2014) 722–730, <https://doi.org/10.1021/cb4008953>.
- [30] S. Gemma, G. Kukreja, G. Campiani, S. Butini, M. Bernetti, B.P. Joshi, L. Savini, N. Basilio, D. Taramelli, V. Yardley, A. Bertamino, E. Novellino, M. Persico, B. Catalanotti, C. Fattorusso, Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling, *Bioorg. Med. Chem. Lett* 17 (2007) 3535–3539, <https://doi.org/10.1016/j.bmcl.2007.04.077>.
- [31] E.D. Thorsett, F.R. Stermitz, Alkylation of haloquinolines by Grignard reagents with nickel-phosphine complex catalysts, *J. Heterocycl. Chem.* 10 (1973) 243–244, <https://doi.org/10.1002/jhet.5570100224>.
- [32] E. Vismara, F. Fontana, F. Minisci, A new method for the oxidation of methyl to formyl groups in heteroaromatic derivatives, *Gazz. Chim. Ital.* 117 (1987) 135–136.
- [33] A. Procopio, M. Gaspari, M. Nardi, M. Oliverio, A. Tagarelli, G. Sindona, Simple and efficient MW-assisted cleavage of acetals and ketals in pure water, *Tetrahedron Lett.* 48 (2007) 8623–8627, <https://doi.org/10.1016/j.tetlet.2007.10.038>.
- [34] P.E. Gordon, A.J. Fry, Hypophosphorous acid-iodine: a novel reducing system. Part 2: reduction of benzhydrols to diarylmethylene derivatives, *Tetrahedron Lett.* 42 (2001) 831–833, [https://doi.org/10.1016/S0040-4039\(00\)02159-6](https://doi.org/10.1016/S0040-4039(00)02159-6).
- [35] N. Boechat, L.C.S. Pinheiro, O.A. Santos-Filho, I.C. Silva, Design and synthesis of new N-(5-Trifluoromethyl)-1H-1,2,4-triazol-3-yl benzenesulfonamides as possible antimalarial prototypes, *Molecules* 16 (2011) 8083–8097, <https://doi.org/10.3390/molecules16098083>.
- [36] N. Boechat, L.C.S. Pinheiro, T.S. Silva, A.C.C. Aguiar, A.S. Carvalho, M.M. Bastos, C.C.P. Costa, S. Pinheiro, A.C. Pinto, J.S. Mendonça, K.D.B. Dutra, A.L. Valverde, O.A. Santos-Filho, I.P. Ceravolo, A.U. Kretli, New trifluoromethyl triazolopyrimidines as Anti-Plasmodium falciparum agents, *Molecules* 17 (2012) 8285–8302, <https://doi.org/10.3390/molecules17078285>.
- [37] Y. Makisumi, Synthesis of potential anticancer agents. IV. 5, 7-disubstituted s-triazolo [2, 3-a] pyrimidines, *Chem. Pharm. Bull. (Tokyo)* 9 (1961) 801–808, <https://doi.org/10.1248/cpb.9.801>.
- [38] Y. Makisumi, Studies on azaindolizine compounds. XIV. Transesterification in s-triazolo [1, 5-a] pyrimidines, *Chem. Pharm. Bull. (Tokyo)* 11 (1963) 845–850, <https://doi.org/10.1248/cpb.11.845>.
- [39] N. Vale, R. Moreira, P. Gomes, Primaquine revisited six decades after its discovery, *Eur. J. Med. Chem.* 44 (2009) 937–953, <https://doi.org/10.1016/j.ejmech.2008.08.011>.
- [40] E.R. Da Silva, N. Boechat, L.C.S. Pinheiro, M.M. Bastos, C.C.P. Costa, J.C. Bartholomeu, T.H. Da Costa, Novel selective inhibitor of leishmania (leishmania) amazonensis arginase, *Chem. Biol. Drug Des.* 86 (2015) 969–978, <https://doi.org/10.1111/cbdd.12566>.
- [41] R. Gujjar, F. El Mazouni, K.L. White, J. White, S. Creason, D.M. Shackleford, X. Deng, W.N. Charman, I. Bathurst, J. Burrows, D.M. Floyd, D. Matthews, F.S. Buckner, S.A. Charman, M.A. Phillips, P.K. Rathod, Lead optimization of aryl and alkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice, *J. Med. Chem.* 54 (2011) 3935–3949, <https://doi.org/10.1021/jm200265b>.
- [42] J.M. Coteron, M. Marco, J. Esquivias, X. Deng, K.L. White, J. White, M. Koltun, F. El Mazouni, S. Kokkonda, K. Katneni, R. Bhamidipati, D.M. Shackleford, I. Angulo-Barturen, S.B. Ferrer, M.B. Jiménez-Díaz, F.J. Gamó, E.J. Goldsmith, W.N. Charman, I. Bathurst, D. Floyd, D. Matthews, J.N. Burrows, P.K. Rathod, S.A. Charman, M.A. Phillips, Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential, *J. Med. Chem.* 54 (2011) 5540–5561, <https://doi.org/10.1021/jm200592f>.
- [43] R. Gujjar, A. Marwaha, F. El Mazouni, J. White, K.L. White, S. Creason, D.M. Shackleford, J. Baldwin, W.N. Charman, F.S. Buckner, S. Charman, P.K. Rathod, M.A. Phillips, Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with

- antimalarial activity in mice, *J. Med. Chem.* 52 (2009) 1864–1872, <https://doi.org/10.1021/jm801343r>.
- [44] G. Camarda, P. Jirawatcharadech, R.S. Priestley, A. Saif, S. March, M.H.L. Wong, S. Leung, A.B. Miller, D.A. Baker, P. Alano, M.J.I. Paine, S.N. Bhatia, P.M. O'Neill, S.A. Ward, G.A. Biagini, Antimalarial activity of primaquine operates via a two-step biochemical relay, *Nat. Commun.* 10 (2019) 3226, <https://doi.org/10.1038/s41467-019-11239-0>.
- [45] P.S. Fasinu, N.P.D. Nanayakkara, Y.-H. Wang, N.D. Chaurasiya, H.M.B. Herath, J.D. McChesney, B. Avula, I. Khan, B.L. Tekwani, L.A. Walker, Formation primaquine-5,6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes, *Malar. J.* 18 (2019) 30, <https://doi.org/10.1186/s12936-019-2658-5>.
- [46] D.A. van Schalkwyk, M.N. Nash, S.H. Shafik, R.L. Summers, A.M. Lehane, P.J. Smith, R.E. Martin, Verapamil-sensitive transport of quinacrine and methylene blue via the plasmodium falciparum chloroquine resistance transporter reduces the parasite's susceptibility to these tricyclic drugs, *J. Infect. Dis.* 213 (2016) 800–810, <https://doi.org/10.1093/infdis/jiv509>.
- [47] L. Lucantoni, R.S. Yerbanga, G. Lupidi, L. Pasqualini, F. Esposito, A. Habluetzel, Transmission blocking activity of a standardized neem (*Azadirachta indica*) seed extract on the rodent malaria parasite *Plasmodium berghei* in its vector *Anopheles stephensi*, *Malar. J.* 9 (2010) 66, <https://doi.org/10.1186/1475-2875-9-66>.
- [48] P.-C. Burda, M.A. Roelli, M. Schaffner, S.M. Khan, C.J. Janse, V.T. Heussler, A plasmodium phospholipase is involved in disruption of the liver stage parasitophorous vacuole membrane, *PLoS Pathog.* 11 (2015), e1004760, <https://doi.org/10.1371/journal.ppat.1004760>.
- [49] P. Pino, R. Caldelari, B. Mukherjee, J. Vahokoski, N. Klages, B. Maco, C.R. Collins, M.J. Blackman, I. Kursula, V. Heussler, M. Brochet, D. Soldati-Favre, A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress, *Science* 80– (358) (2017) 522, <https://doi.org/10.1126/science.aaf8675>. LP – 528.